Augmedix (AUGX) S-1/A 4 Oct 21 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	Augmedix, Inc.
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Central Index Key	0001769804
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 16,353,000	$ 20,762,000	$ 9,603,266
Restricted cash	125,000	2,211,000	2,000,119
Accounts receivable, net of allowance for doubtful accounts	3,775,000	2,693,000	2,290,803
Prepaid expenses and other current assets	1,457,000	1,104,000	458,509
Total current assets	21,710,000	26,770,000	14,352,697
Property and equipment, net	964,000	992,000	1,213,026
Restricted cash, non-current	207,000
Deposits	69,000	173,000	173,294
Total assets	22,950,000	27,935,000	15,739,017
Current liabilities:
Note payable, current portion		2,894,000	2,893,667
Subordinated note payable, current portion		3,719,000
Accounts payable	1,221,000	259,000	640,896
Accrued expenses and other current liabilities	2,826,000	3,109,000	2,766,248
Deferred revenue	5,885,000	5,439,000	5,510,460
Customer deposits	747,000	1,053,000	1,052,900
Total current liabilities	10,679,000	16,473,000	12,864,171
Note payable, net of current portion	2,180,000	2,180,000
Subordinated note payable, net of current portion		6,158,000	9,721,608
Loan payable	14,529,000
Deferred rent, net of current portion	254,000		20,877
Preferred stock warrant liability			4,391,372
Total liabilities	27,642,000	24,811,000	26,998,028
Commitments and contingencies (Note 10)
Convertible preferred stock			53,882,460
Stockholders’ equity (deficit):
Preferred stock value
Common stock value	3,000	3,000	83
Additional paid-in capital	88,773,000	87,051,000	3,174,102
Accumulated deficit	(93,419,000)	(83,878,000)	(68,274,256)
Accumulated other comprehensive loss	(49,000)	(52,000)	(41,400)
Total stockholders’ equity (deficit)	(4,692,000)	3,123,610	(65,141,471)
Total liabilities and stockholders’ (deficit) equity	$ 22,950,000	$ 27,935,000	$ 15,739,017

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts (in Dollars)	$ 10,000	$ 10,000	$ 9,882
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	27,110,934	26,859,850	833,505
Common Stock, shares outstanding	27,110,934	26,859,850	833,505

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 5,173,000	$ 3,725,000	$ 9,963,000	$ 7,695,000	$ 16,483,184	$ 14,107,681
Cost of revenues	2,761,000	2,195,000	5,426,000	4,785,000	9,689,527	9,428,454
Gross profit	2,412,000	1,530,000	4,537,000	2,910,000	6,793,657	4,679,227
Operating expenses:
General and administrative	3,220,000	2,276,000	6,749,000	5,144,000	11,566,585	10,861,392
Sales and marketing	1,728,000	819,000	3,302,000	2,058,000	4,397,834	3,583,285
Research and development	1,499,000	985,000	2,925,000	2,476,000	4,521,583	6,977,259
Total operating expenses	6,447,000	4,080,000	12,976,000	9,678,000	20,486,002	21,421,936
Loss from operations	(4,035,000)	(2,550,000)	(8,439,000)	(6,768,000)	(13,692,345)	(16,742,709)
Other income (expenses):
Interest expense	(605,000)	(439,000)	(1,296,000)	(795,000)	(1,453,022)	(2,812,361)
Interest income	3,000	3,000	7,000	3,000	10,835	6,268
Other income (expenses)		27,000	187,000	(137,000)	(469,184)	1,050,461
Total other income (expenses), net	(602,000)	(409,000)	(1,102,000)	(929,000)	(1,911,371)	(1,755,632)
Net loss	(4,637,000)	(2,959,000)	(9,541,000)	(7,697,000)	(15,603,716)	(18,498,341)
Other comprehensive (loss) income:
Foreign exchange translation adjustment	(1,000)	(11,000)	3,000	(12,000)	(10,762)	6,903
Total comprehensive loss	$ (4,638,000)	$ (2,970,000)	$ (9,538,000)	$ (7,709,000)	$ (15,614,478)	$ (18,491,438)
Net loss per share of common stock, basic and diluted (in Dollars per share)	$ (0.17)	$ (3.54)	$ (0.35)	$ (9.21)	$ (2.22)	$ (22.24)
Weighted average shares of common stock outstanding, basic and diluted (in Shares)	27,020,437	835,429	26,941,215	835,313	7,033,670	831,590

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Changes in Stockholders’ (Deficit) Equity - USD ($)	ConvertiblePreferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2018	$ 38,257,039	$ 83	$ 2,773,470	$ (49,775,915)	$ (48,303)	$ (47,050,665)
Balance (in Shares) at Dec. 31, 2018	8,050,502	829,938
Conversion of bridge loan to Series B convertible preferred stock	$ 2,609,321
Conversion of bridge loan to Series B convertible preferred stock (in Shares)	1,281,631
Beneficial conversion feature related to convertible notes payable	$ 1,078,769
Issuance of Series B convertible preferred stock, net of issuance costs	$ 11,937,331
Issuance of Series B convertible preferred stock, net of issuance costs (in Shares)	5,306,910
Repurchase of common stock
Repurchase of common stock (in Shares)		(346)
Exercise of common stock options			3,533			3,533
Exercise of common stock options (in Shares)		3,913
Stock-based compensation expense			397,099			397,099
Foreign currency translation adjustment					6,903	6,903
Net loss				(18,498,341)		(18,498,341)
Balance at Dec. 31, 2019	$ 53,882,460	$ 83	3,174,102	(68,274,256)	(41,400)	(65,141,471)
Balance (in Shares) at Dec. 31, 2019	14,639,043	833,505
Issuance of Series B convertible preferred stock, net of issuance costs	$ 401,000
Issuance of Series B convertible preferred stock, net of issuance costs (in Shares)	173,752
Exercise of common stock options			2,000			2,000
Exercise of common stock options (in Shares)		1,924
Stock-based compensation expense			97,000			97,000
Foreign currency translation adjustment					(1,000)	(1,000)
Net loss				(4,738,000)		(4,738,000)
Balance at Mar. 31, 2020	$ 54,283,000		3,273,000	(73,012,000)	(42,000)	(69,781,000)
Balance (in Shares) at Mar. 31, 2020	14,812,795	835,429
Balance at Dec. 31, 2019	$ 53,882,460	$ 83	3,174,102	(68,274,256)	(41,400)	(65,141,471)
Balance (in Shares) at Dec. 31, 2019	14,639,043	833,505
Issuance of Series B convertible preferred stock, net of issuance costs	$ 400,504
Issuance of Series B convertible preferred stock, net of issuance costs (in Shares)	173,752
Conversion of convertible preferred stock to common stock	$ (54,242,464)	$ 1,480	54,240,984			54,242,464
Conversion of convertible preferred stock to common stock (in Shares)	(14,804,274)	14,804,274
Reclassification of convertible preferred stock warrant liability			5,230,687			5,230,687
Payment to unaccredited investors upon consummation of the Merger	$ (40,500)	$ (18)	(546,183)			(546,201)
Payment to unaccredited investors upon consummation of the Merger (in Shares)	(8,521)	(183,510)
Issuance of common stock to former stockholders of Malo Holdings Corporation		$ 217	(52,261)			(52,044)
Issuance of common stock to former stockholders of Malo Holdings Corporation (in Shares)		2,166,667
Sale of common stock in private placement		$ 914	24,255,180			24,256,094
Sale of common stock in private placement (in Shares)		9,138,855
Exercise of common stock options		$ 10	80,477			80,487
Exercise of common stock options (in Shares)		100,059
Stock-based compensation expense			668,072			668,072
Foreign currency translation adjustment					(10,762)	(10,762)
Net loss				(15,603,716)		(15,603,716)
Balance at Dec. 31, 2020		$ 2,686	87,051,058	(83,877,972)	(52,162)	3,123,610
Balance (in Shares) at Dec. 31, 2020		26,859,850
Balance at Mar. 31, 2020	$ 54,283,000		3,273,000	(73,012,000)	(42,000)	(69,781,000)
Balance (in Shares) at Mar. 31, 2020	14,812,795	835,429
Stock-based compensation expense			295,000			295,000
Foreign currency translation adjustment					(11,000)	(11,000)
Net loss				(2,959,000)		(2,959,000)
Balance at Jun. 30, 2020	$ 54,283,000		3,568,000	(75,971,000)	(53,000)	(72,456,000)
Balance (in Shares) at Jun. 30, 2020	14,812,795	835,429
Balance at Dec. 31, 2020		$ 2,686	87,051,058	(83,877,972)	(52,162)	3,123,610
Balance (in Shares) at Dec. 31, 2020		26,859,850
Issuance of common stock warrants			395,000			395,000
Issuance of common stock in connection with exercise of warrants			4,000			4,000
Issuance of common stock in connection with exercise of warrants (in Shares)		4,208
Stock-based compensation expense			384,000			384,000
Foreign currency translation adjustment					4,000	4,000
Net loss				(4,904,000)		(4,904,000)
Balance at Mar. 31, 2021		$ 3,000	87,834,000	(88,782,000)	(48,000)	(993,000)
Balance (in Shares) at Mar. 31, 2021		26,864,058
Balance at Dec. 31, 2020		$ 2,686	87,051,058	(83,877,972)	(52,162)	3,123,610
Balance (in Shares) at Dec. 31, 2020		26,859,850
Issuance of common stock to former stockholders of Malo Holdings Corporation						7,000
Issuance of common stock to former stockholders of Malo Holdings Corporation (in Shares)		2,166,667
Balance at Jun. 30, 2021		$ 3,000	88,773,000	(93,419,000)	(49,000)	(4,692,000)
Balance (in Shares) at Jun. 30, 2021		27,110,934
Balance at Mar. 31, 2021		$ 3,000	87,834,000	(88,782,000)	(48,000)	(993,000)
Balance (in Shares) at Mar. 31, 2021		26,864,058
Issuance of common stock to service provider			600,000			600,000
Issuance of common stock to service provider (in Shares)		120,000
Exercise of common stock options			100,000			100,000
Exercise of common stock options (in Shares)		126,876
Stock-based compensation expense			239,000			239,000
Foreign currency translation adjustment					(1,000)	(1,000)
Net loss				(4,637,000)		(4,637,000)
Balance at Jun. 30, 2021		$ 3,000	$ 88,773,000	$ (93,419,000)	$ (49,000)	$ (4,692,000)
Balance (in Shares) at Jun. 30, 2021		27,110,934

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (9,541,000)	$ (7,697,000)	$ (15,603,716)	$ (18,498,341)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	367,000	432,000	867,000	949,006
Stock-based compensation	623,000	392,000	668,072	397,099
Non-cash interest expense	190,000	164,000	155,738	1,421,655
Change in fair value of preferred stock warrant liability		186,000	743,837	71,635
Non-cash portion of loss on debt extinguishment	161,000
Allowance for doubtful accounts				(2,941)
Deferred rent	233,000	(104,000)	(210,010)	(217,756)
Changes in operating assets and liabilities:
Accounts receivable	(1,082,000)	(613,000)	(401,737)	(126,200)
Prepaid expenses and other current assets	351,000	(98,000)	(646,925)	(38,950)
Deposits				(40,882)
Accounts payable	635,000	(131,000)	(396,863)	373,747
Accrued expenses and other current liabilities	(236,000)	(475,000)	497,656	530,280
Deferred revenue	446,000	(608,000)	(71,905)	644,961
Customer deposits				(108,750)
Net cash used in operating activities	(7,853,000)	(8,552,000)	(14,398,853)	(14,645,437)
Cash flows from investing activities:
Purchase of property and equipment	(318,000)	(315,000)	(647,015)	(823,013)
Net cash used in investing activities	(318,000)	(315,000)	(647,015)	(823,013)
Cash flows from financing activities:
Cash paid in connection with the Merger, net of cash acquired			(46,044)
Proceeds from loan	15,000,000
Payment to unaccredited investors of Augmedix Operating Corporation	(22,000)		(555,174)
Proceeds of notes payable		2,180,000	2,180,300
Repayment of notes payable	(12,966,000)			(1,357,837)
Proceeds from sale of common stock			27,416,565
Proceeds from issuance of convertible preferred stock			499,999	15,271,440
Proceeds from issuance of convertible notes payable		500,000		3,303,535
Payment of financing costs	(232,000)	(4,000)	(3,159,488)	(52,893)
Proceeds from exercise of common stock warrants	4,000
Proceeds from exercise of stock options	100,000	2,000	80,487	3,533
Net cash provided by financing activities	1,884,000	2,678,000	26,416,645	17,167,778
Effect of exchange rate changes on cash and restricted cash	(1,000)	(3,000)	(1,176)	(10,397)
Net increase/decrease in cash and restricted cash	(6,288,000)	(6,192,000)	11,369,601	1,688,931
Cash and restricted cash at beginning of period	22,972,986	11,603,385	11,603,385	9,914,454
Cash and restricted cash at end of period	16,685,000	5,411,000	22,972,986	11,603,385
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	830,000	708,000	1,265,608	1,367,929
Supplemental schedule of non-cash investing and financing activities:
Fair value of warrants issued in connection with loan	395,000
Fair value of common stock issued to service provider	600,000
Property, plant, and equipment in accounts payable	$ 21,000
Conversion of convertible preferred stock to shares of common stock			54,242,264
Amounts due to unaccredited investors of Augmedix Operating Corporation			31,527
Financing fees in accrued expenses			5,000
Issuance of convertible preferred stock in exchange for convertible notes payable and accrued interest				3,319,283
Beneficial conversion feature related to convertible notes payable				$ 1,078,769

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Augmedix, Inc. (the “Company” or “Augmedix”) (formerly known as Malo Holdings Corporation) provides software compatible with off -the-shelf -patient -party Malo Holdings Corporation Merger On October Private Augmedix was incorporated in the state of Delaware in April 2013 and is headquartered in San Francisco, California. Private Augmedix has two wholly owned subsidiaries, Augmedix BD Limited, established in February 2015, and Augmedix Solutions Pvt. Ltd., established in February 2019, which are entities formed in Bangladesh and India, respectively. Liquidity and Going Concern In accordance with Financial Accounting Standards (“FASB”) Accounting Standards Update (“ASU”) No. 2014 -15 -40 The Company has incurred recurring losses since its inception, including net losses of $4.6 -Q Risks and Uncertainties The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from similar products and larger companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions. In December 2019, a novel strain of coronavirus disease (“COVID -19 -19 -19 -essential -19 -19 -19 As the impact of COVID -19	1. Organization and Nature of Business Augmedix, Inc. (formerly known as Malo Holdings Corporation, the “Company”) was incorporated in the State of Delaware on December On October Private Augmedix was incorporated in the state of Delaware in April 2013 and is headquartered in San Francisco, California. Private Augmedix has two wholly owned subsidiaries, Augmedix BD Limited, established in February 2015, and Augmedix Solutions Pvt. Ltd., established in February 2019, which are entities formed in Bangladesh and India, respectively. Subsequent to the Merger, the Company provides virtual medical documentation services for clinicians. At the Effective Time, each of Private Augmedix’s shares of Series B convertible preferred stock and common stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive (a) 0.420864013 In addition, pursuant to the Merger Agreement, (i) options and stock appreciation rights to purchase shares of Private Augmedix’s common stock issued and outstanding immediately prior to the closing of the Merger under the Private Augmedix 2013 Equity Incentive Plan were assumed and converted into options and stock appreciation rights to purchase shares of the Company’s common stock, (ii) warrants to purchase shares of Private Augmedix’s Series B convertible preferred stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into warrants to purchase shares of the Company’s common stock, and (iii) warrants to purchase shares of Private Augmedix’s common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into warrants to purchase shares of the Company’s common stock. The Merger was accounted for as a “reverse acquisition” since, immediately following the consummation of the Merger (the “Closing”), Private Augmedix effectively controlled the post -combination -up -casted -in Liquidity and Going Concern In accordance with Financial Accounting Standards (“FASB”) Accounting Standards Update (“ASU”) No. 2014 -15 -40 The Company has incurred recurring losses since its inception, including net losses of $15.6 Risks and Uncertainties The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from similar products and larger companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions. In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID -19 -19 -19 -19

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of presentation and summary of significant accounting policies	2. Basis of presentation and summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standard Updates (“ASUs”) of the FASB. The accompanying unaudited interim condensed consolidated financial statements include the accounts of Augmedix, Inc. and its wholly owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited and Augmedix Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of June -K Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments involve the identification of performance obligations in revenue recognition and the valuation of the warrant liability and stock -based Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making Foreign Currency Transactions, Translations and Foreign Operations The functional currency of the Bangladesh and India subsidiaries are the Bangladeshi Taka and Indian Rupee, respectively. All assets and liabilities denominated in each entity’s functional currency are translated into the U.S. dollar using the exchange rate in effect as of the balance sheet dates. Expenses are translated using the weighted average exchange rate for the reporting period. The resulting translation gains and losses are recorded within the unaudited interim condensed consolidated statements of operations and comprehensive loss and as a separate component of stockholders’ (deficit) equity. Foreign currency transaction gains and losses are recorded within other income (expense) in the accompanying unaudited interim condensed consolidated statements of operations and comprehensive loss. Transaction gains and losses were not material for the three and six months ended June Operations outside the United States are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange. Concentrations of Credit Risk and Major Customers Financial instruments at June The Company’s cash is deposited with major financial institutions in the United States, Bangladesh and India. At times, deposits in financial institutions located in the United States may be in excess of the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation (FDIC). Cash deposits at foreign financial institutions are not insured by government agencies of Bangladesh and India. To date, the Company has not experienced any losses on its cash deposits. The Company’s accounts receivable are derived from revenue earned from customers located in the United States. Major customers are defined as those generating revenue in excess of 10% of the Company’s annual revenue. The Company had three major customers during the three and six months ended June Restricted Cash Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s credit card facility balances and to collateralize a letter of credit in the name of the Company’s landlord pursuant to a certain operating lease. The following table provides a reconciliation of the components of cash and restricted cash reported in the Company’s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows: June 30, (in thousands) 2021 2020 Cash $ 16,353 $ 3,411 Restricted cash 125 2,000 Restricted cash, non-current 207 — Total cash and restricted cash presented in the condensed consolidated statements of cash flows $ 16,685 $ 5,411 Impairment of Long-Lived Assets The Company reviews its long -lived Revenue Recognition ASC Topic 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The core principle, involving a five -step The Company derives its revenue through a recurring subscription model. The Company enters into contracts or agreements with its customers with a general initial term of one year. Customers are invoiced in advance and must generally pay an upfront implementation fee. The upfront implementation fee is deferred and recognized over the initial term of the contract and customer prepayments are deferred and included in the accompanying unaudited interim condensed consolidated balance sheets in deferred revenues. Revenues are recognized when the professional services are provided to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company’s revenues are earned from customers located only in the United States. After the initial term, contracts are cancellable by the customer at their discretion with a 90 day notice. The Company determines revenue recognition through the following steps: • • • • • Except for two U.S. state sales tax jurisdictions, applicable taxes, including local, sales, value added tax, etc., are the responsibility of the customer to self -assess The Company also generates revenue from data service projects, which includes projects to complete certain tasks or provide other services to customers. These services represent separate performance obligations which are recognized as revenue as the services are performed. Contract Balances and Accounts Receivable Changes in the contract liability deferred revenue account were as follows for the six months ended June (in thousands) Six Months Ended Year Ended Balance, beginning of period $ 5,439 $ 5,510 Deferral of revenue 10,409 16,412 Recognition of unearned revenue (9,963 ) (16,483 ) Balance, end of period $ 5,885 $ 5,439 Accounts receivable, net from customers was $3.8 Deferred revenue consists of billings or payments received in advance of revenue recognized for the Company’s services, as described above, and is recognized as revenue as earned. As of June Stock-Based Compensation The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees based on the estimated fair value of the award on the grant date. The fair value of each option award is estimated using either a Black -Scholes -pricing -line Estimating the fair market value of options requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock prior to the Merger (Note 1), the expected life of the options, stock price volatility, the risk -free -condition Advertising Costs All advertising costs are expensed as incurred and included in sales and marketing expenses. In April 2021, the Company issued 120,000 -year Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the six months ended June The following potentially dilutive securities have been excluded from the computation of diluted weighted -average -dilutive June 30, June 30, Convertible preferred stock — 14,812,795 Convertible preferred stock warrants — 2,767,836 Common stock warrants 3,333,791 5,585 Stock options 6,365,965 4,465,548 9,699,756 22,051,764 Recent Accounting Pronouncements In February 2016, the FASB issued ASC Topic 842, Leases, (“Topic 842”). This standard requires all entities that lease assets with terms of more than 12 -05 In August 2020, the FASB issued ASU Update No. 2020 -06 -20 -40 In June 2016, the FASB issued ASU 2016 -13	2. Basis of presentation and summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by ASUs of the FASB. The accompanying consolidated financial statements include the accounts of Augmedix, Inc. and its wholly owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited and Augmedix Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments involve the identification of performance obligations in revenue recognition and the valuation of the warrant liability and stock -based Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making Reverse Stock Split In March 2019, the Board of Directors approved an amendment of the Company’s Certificate of Incorporation approving a 10:1 reverse stock split on all authorized and outstanding shares of common stock and preferred stock. All references to common stock share, preferred stock share and per share amounts in these consolidated financial statements have been retroactively adjusted to reflect, where applicable, the reverse stock split, as indicated. Foreign Currency Transactions, Translations and Foreign Operations The functional currency of the Bangladesh and India subsidiaries are the Bangladeshi Taka and Indian Rupee, respectively. All assets and liabilities denominated in each entity’s functional currency are translated into the U.S. dollar using the exchange rate in effect as of the balance sheet dates. Expenses are translated using the weighted average exchange rate for the reporting period. The resulting translation gains and losses are recorded within the consolidated statements of operations and comprehensive loss and as a separate component of stockholders’ equity (deficit). Foreign currency transaction gains and losses are recorded within other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. Transaction gains and losses were not material for the years ended December Operations outside the United States are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange. Concentrations of Credit Risk and Major Customers Financial instruments at December The Company’s cash is deposited with major financial institutions in the United States, Bangladesh and India. At times, deposits in financial institutions located in the United States may be in excess of the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation (FDIC). Cash deposits at foreign financial institutions are not insured by government agencies of Bangladesh and India. To date, the Company has not experienced any losses on its cash deposits. The Company’s accounts receivable are derived from revenue earned from customers located in the United States. Major customers are defined as those generating revenue in excess of 10% of the Company’s annual revenue. The Company had two major customers during the year ended December and 20% of revenue for the year ended December Restricted Cash Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s Note Payable. The following table provides a reconciliation of the components of cash and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows: December 31, 2020 2019 Cash $ 20,762,084 $ 9,603,266 Restricted cash 2,210,902 2,000,119 Total cash and restricted cash presented in the consolidated statements of cash flows $ 22,972,986 $ 11,603,385 Accounts receivable and allowance for doubtful accounts Accounts receivable primarily relates to amounts due from customers, which are typically due within 30 to 60 days from invoice date. The Company provides credit to its customers in the normal course of business and maintains allowances for potential credit losses. The Company does not require collateral or other security for accounts receivable. To reduce credit risk with accounts receivable, the Company performs ongoing evaluations of its customers’ financial condition. Historically, such losses have been immaterial and within management’s expectations. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. The Company depreciates computer hardware, software and equipment using the straight -line -line Impairment of Long-Lived Assets The Company reviews its long -lived Fair Value of Financial Instruments Certain assets and liabilities of the Company are carried at fair value under GAAP. The Company uses a three -level -based -specific at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with those financial instruments. The three -level Level 1: Level 2: Level 3: An asset or liability’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Convertible Preferred Stock Warrants Accounting standards require that freestanding warrants and similar instruments, due to settlement features of the financial instruments, should be accounted for as a preferred stock warrant liability even though the underlying shares of capital stock may be classified as equity. Such warrants are measured and recognized at fair value, and subject to re -measurement Revenue Recognition ASC Topic 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The core principle, involving a five -step The Company derives its revenue through a recurring subscription model. The Company enters into contracts or agreements with its customers with a general initial term of one year. Customers are invoiced in advance and must generally pay an upfront implementation fee. The upfront implementation fee is deferred and recognized over the initial term of the contract and customer prepayments are deferred and included in the accompanying consolidated balance sheets in deferred revenues. Revenues are recognized when the professional services are provided to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company’s revenues are earned from customers primarily located in the United States. After the initial term, contracts are cancellable by the customer at their discretion with a 90 day notice. The Company determines revenue recognition through the following steps: • • • • • Except for two U.S. state sales tax jurisdictions, applicable taxes, including local, sales, value added tax, etc., are the responsibility of the customer to self -assess The Company also generates revenue from data service projects, which includes discrete projects to complete certain tasks or provide other services to customers. These services represent separate performance obligations which are recognized as revenue as the services are performed. Contract Balances and Accounts Receivable Changes in the contract liability deferred revenue account were as follows for the years ended December Years Ended 2020 2019 Balance, beginning of year $ 5,510,460 $ 4,865,499 Deferral of revenue 16,411,279 14,752,642 Recognition of unearned revenue (16,483,184 ) (14,107,681 ) Balance, end of year $ 5,438,555 $ 5,510,460 Accounts receivable, net from customers was $2,692,540 and $2,290,803 as of December Deferred revenue consists of billings or payments received in advance of revenue recognized for the Company’s services, as described above, and is recognized as revenue as earned. As of December Customer Deposits Customer deposits consists of deposits received by the Company, as required on certain contracts and agreements, which are refundable at the termination of the contract. Cost of Revenue The Company’s cost of revenue consists primarily of salaries and related expenses, overhead, contract labor and third party services from MDS Vendors, depreciation expense related to the glass equipment and information technology costs incurred directly in the Company’s revenue -generating Stock-Based Compensation The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees based on the estimated fair market value of the award on the grant date. The Company uses the Black -Scholes -line -based On January -7 Compensation — Stock Compensation (ASC Topic 718): Improvements to Nonemployee Share -Based Payment Accounting -based -based -7 Estimating the fair market value of options requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock, the expected life of the options, stock price volatility, the risk -free -Scholes -pricing Research and Development Costs Research and development costs are expensed as incurred and consist primarily of personnel -related Advertising Costs All advertising costs are expensed as incurred and included in sales and marketing expenses. Advertising expenses incurred by the Company were $155,835 and $51,919 for the years ended December Comprehensive Loss The Company reports comprehensive loss, which includes the Company’s net loss as well as changes in equity from non -stockholder Income Taxes Income taxes are accounted for under the asset and liability method as required by FASB ASC Topic 740, Income Taxes FASB ASC Subtopic 740 -10 Accounting for Uncertainty of Income Taxes -10 -10 Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the years ended December The following potentially dilutive securities have been excluded from the computation of diluted weighted -average -dilutive December 31, 2020 2019 Convertible preferred stock — 14,639,043 Convertible preferred stock warrants — 2,710,498 Common stock warrants 2,991,499 5,585 Stock options 4,211,857 2,749,298 7,203,356 20,104,424 Recent Accounting Pronouncements In February 2016, the FASB issued ASC Topic 842, Leases, -05 In August 2016, the FASB issued ASU No. 2016 -15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments -15 In August 2018, the FASB issued ASU 2018 -13 Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurements In August 2020, the FASB issued ASC Update No. 2020 -06 Debt — Debt with Conversion and Other Options (Subtopic 470 -20 ) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815 -40 ): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In June 2016, the FASB issued ASU 2016 -13 Financial Instruments — Credit Losses,

Malo Holdings Corporation Merge

Malo Holdings Corporation Merger	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Business Combinations [Abstract]
Malo Holdings Corporation Merger	3. Malo Holdings Corporation Merger As described in Note -combination As part of the reverse recapitalization, the Company obtained approximately $4,000 of cash and assumed payables and accruals of approximately $56,000, of which $50,000 was paid at closing. Additionally, transaction costs of approximately $0.8	3. Malo Holdings Corporation Merger As described in Note -combination As part of the reverse recapitalization, the Company obtained approximately $4,000 of cash and assumed payables and accruals of approximately $56,000, of which $50,000 was paid at closing. Additionally, transaction costs of approximately $753,000 consisting of legal, accounting, financial advisory and other professional fees were expensed as incurred and are recorded in general and administrative expenses in the accompanying consolidated statements of operations for the year ended December

Fair Value Measurements

Fair Value Measurements	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Fair Value of Financial Instruments The carrying amounts of cash, restricted cash, accounts receivable, prepaid expenses, accounts payable, and customer deposits approximate fair value due to their short -term	4. Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis: December 31, 2020 (Level 1) (Level 2) (Level 3) Liabilities Preferred stock warrant liability $ — $ — $ — December 31, 2019 (Level 1) (Level 2) (Level 3) Liabilities Preferred stock warrant liability $ — $ — $ 4,391,372 The Company’s Series B preferred stock warrants were classified as liabilities, recorded at fair value and subject to re -measurement The Series B preferred stock warrant liabilities are estimated using an option pricing model. The significant assumptions used in valuing the warrants include expected term, expected volatility, risk -free -average October 5, December 31, 2020 2019 Risk-free interest rate 0.7 % 1.9 % Remaining contractual life of warrant (years) 8.9 9.7 Expected volatility 57.8 % 50.9 % Annual dividend yield 0 % 0 % Fair value of Series B convertible preferred stock $ 1.26 $ 1.14 The reconciliation of the Series B preferred stock warrant liability measured at fair value, until the reclassification into equity at the time of the Merger, on a recurring basis using significant unobservable inputs (Level 3) was as follows: Balance, January 1, 2019 $ 328,559 Issuance of warrants in connection with Series B financing 3,991,178 Change in fair value recorded as other expense 71,635 Balance, December 31, 2019 4,391,372 Issuance of warrants in connection with Series B financing 95,478 Change in fair value recorded as other expense 743,837 Reclassification to equity (5,230,687 ) Balance, December 31, 2020 $ — Fair Value of Financial Instruments The carrying amounts of cash, restricted cash, accounts receivable, prepaid expenses, accounts payable, customer deposits, and note payable approximate fair value due to their short -term

Property and Equipment

Property and Equipment	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment, net Property and equipment, net consists of the following: (in thousands) June 30, December 31, 2020 Computer hardware, software and equipment $ 5,893 $ 5,557 Leasehold improvements 2,184 2,186 Furniture and fixtures 272 271 8,349 8,014 Less: accumulated depreciation (7,385 ) (7,022 ) Property and equipment, net $ 964 $ 992 The Company recorded depreciation and amortization expense of $0.2	5. Property and Equipment Property and equipment consists of the following: December 31, 2020 2019 Computer hardware, software and equipment $ 5,557,034 $ 5,039,545 Leasehold improvements 2,186,239 2,072,006 Furniture and fixtures 270,943 262,865 8,014,216 7,374,416 Less: accumulated depreciation and amortization (7,021,842 ) (6,161,390 ) $ 992,374 $ 1,213,026 The Company recorded depreciation and amortization expense of $867,000 and $949,006 during the years ended December

Accrued expenses and other curr

Accrued expenses and other current liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consists of the following: (in thousands) June 30, December 31, Accrued compensation $ 1,556 $ 1,711 Accrued other 466 612 Accrued vendor partner liabilities 627 559 Deferred rent — 21 Accrued professional fees 125 151 Accrued VAT and other taxes 52 55 $ 2,826 $ 3,109	6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consists of the following: December 31, 2020 2019 Accrued compensation $ 1,711,377 $ 1,196,723 Accrued other 611,947 530,924 Accrued vendor partner liabilities 559,478 769,351 Deferred rent 20,877 210,010 Accrued professional fees 150,859 36,227 Accrued VAT and other taxes 54,755 23,013 $ 3,109,293 $ 2,766,248

Debt

Debt	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	7. Debt Note Payable In June 2015, the Company entered into a loan and security agreement, as amended, (“Agreement”) with a commercial bank. The Agreement allowed for borrowings of up to $3.5 Outstanding borrowings under the Agreement were secured by substantially all assets of the Company, and the Company was required to maintain certain financial and non -financial In October 2018, in connection with the issuance of Series A convertible preferred stock (Note 8), the Company cancelled warrants previously issued to the commercial bank and issued in its place warrants to purchase 234 and 91 Subordinated Note Payable In May 2017, the Company entered into a loan and security agreement, as amended, (“Sub Agreement”) with a lending institution for borrowings of up to $10.0 Outstanding borrowings under the Sub Agreement were collateralized by substantially all assets of the Company and were subordinate to any outstanding borrowings under the Agreement. Borrowings under the Sub Agreement were subject to certain financial and non -financial Paycheck Protection Program (PPP Loan) On April -month -24 -term On November Loan and Security Agreement On March -half As of June -term At June (in thousands) 2021 (remaining six months) $ — 2022 1,500 2023 6,000 2024 6,000 2025 1,500 15,000 End of term charge 1,125 16,125 Less unamortized debt discount (1,596 ) Loan Agreement borrowing net of discount 14,529 Less current portion — Loan Agreement borrowings, non-current portion $ 14,529 In connection with the Loan Agreement, the Company issued the Lender warrants with a fair value of $0.4 The Company recorded the final payment of $1.1 The Company and Lender also entered into a Co -Investment	7. Debt Note Payable In June 2015, the Company entered into a loan and security agreement (“Agreement”) with a commercial bank. The Agreement allowed for borrowings of up to $3,500,000. Outstanding borrowings under the Agreement bear interest at the prime rate of interest plus 0.5% (3.62% and 5.25% at December -month Outstanding borrowings under the Agreement are secured by substantially all assets of the Company, and the Company is required to maintain certain financial and non -financial In October 2018, in connection with the issuance of Series A convertible preferred stock (Note 8), the Company cancelled warrants previously issued to the commercial bank and issued in its place warrants to purchase 234 and 91 Subordinated Note Payable In May 2017, the Company entered into a loan and security agreement (“Sub Agreement”) with a lending institution for borrowings of up to $10,000,000. At December Outstanding borrowings under the Sub Agreement are collateralized by substantially all assets of the Company and are subordinate to any outstanding borrowings under the Agreement. Borrowings under the Sub Agreement are subject to certain financial and non -financial In August 2019, the Company amended the Sub Agreement (“Amended Sub Agreement”) to extend the interest -only -only Pursuant to the Sub Agreement, a final payment of $650,000 is payable at the maturity date in April 2023. The Company recorded the final payment as both a discount and an increase to the principal amount of the debt. The Company also capitalized certain lender and legal costs associated with the Sub Agreement totaling $279,757, which were recorded as a discount to the Sub Agreement. The aggregate discount of $1,195,012 is being amortized to interest expense over the repayment term of the Sub Agreement. The Company amortized $105,739 and $327,138 of the discount to interest expense during the years ended December In connection with the Sub Agreement, the Company issued a warrant to purchase 3,376 -2 In connection with an amendment to the Sub Agreement in May 2018, the warrant to purchase 3,376 -2 -to-Play -1 -1 -1 -1 At December Years ending December 31: 2021 $ 3,719,265 2022 4,190,960 2023 1,511,938 9,422,163 End of term charge 650,000 10,072,163 Less unamortized debt discount (194,816 ) Sub agreement borrowing net of discount 9,877,347 Less current portion (3,719,265 ) Sub agreement borrowings, non-current portion $ 6,158,082 Convertible Promissory Notes In August 2019, the Company issued convertible promissory notes to certain existing shareholders and received cash proceeds of $3,303,535. The notes accrued simple interest of 6% per year and, if not converted, were to mature in January 2020. All principal and interest were due at maturity. The convertible promissory notes contained a contingent beneficial conversion feature whereby the convertible promissory notes automatically convert to capital stock that is sold in a qualified financing that raises aggregate gross proceeds in excess of $14,700,000. The conversion price was 90% of the lowest selling price per share in the qualified financing. In September 2019, the Company completed a qualified financing (Note 8) and the principal amount plus $15,748 of accrued interest converted into 1,281,631 Paycheck Protection Program On April -month at any time prior to maturity without penalty. The Company may apply for forgiveness of amounts due under the PPP Loan, with the amount of potential loan forgiveness to be calculated in accordance with the requirements of the CARES Act based on payroll costs, any mortgage interest payments, any covered rent payments and any covered utilities payments during the 8 -24 -term On November

Common Stock, Preferred Stock a

Common Stock, Preferred Stock and Convertible Preferred Stock	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Common Stock, Preferred Stock and Convertible Preferred Stock	8. Common Stock, Preferred Stock and Convertible Preferred Stock Common Stock The Company is authorized to issue 500,000,000 -cumulative In connection with the Merger, as discussed in Note Common Stock Warrants At June Expiration Date Shares of common stock issuance Exercise June 11, 2025 234 $ 96.24 November 13, 2025 218,078 $ 3.00 July 28, 2027 91 $ 106.17 August 28, 2028 1,052 $ 39.76 September 2, 2029 2,767,836 $ 2.88 Earlier of March 24, 2031 and the third anniversary of the Company’s listing on Nasdaq 346,500 $ 3.00 3,333,791 Preferred Stock The Company is authorized to issue 10,000,000 Convertible Preferred Stock In February 2020, Private Augmedix raised $0.5 In connection with the Merger, as discussed in Note Series B Convertible Preferred Stock Warrants In August 2019, in connection with amending its Sub Agreement (Note 7), the Company issued a warrant to purchase 580,383 -remeasurement -measurement	8. Common Stock, Preferred Stock and Convertible Preferred Stock Common Stock The Company is authorized to issue 500,000,000 -cumulative In connection with the Merger, as discussed in Note Following the Effective Time of the Merger, the Company sold 8,472,188 -subscriptions -subscribed In November 2020, the Company sold 666,667 additional shares of common stock pursuant to an additional closing of the Private Placement (“Additional Closing”) for aggregate gross proceeds of $2.0 Common Stock Warrants In October 2018 and August 2019, the Company issued warrants to nonemployees to purchase 1,052 and 4,208 At December Expiration Date Shares of common stock issuance upon exercise of warrants Exercise August 7, 2024 4,208 $ 0.86 June 11, 2025 234 $ 96.24 November 13, 2025 218,078 $ 3.00 July 28, 2027 91 $ 106.17 August 28, 2028 1,052 $ 39.76 September 2, 2029 2,767,836 $ 2.88 2,991,499 Preferred Stock The Company is authorized to issue 10,000,000 Convertible Preferred Stock In connection with the Merger, as discussed in Note As of December Shares Issued and Outstanding Series A 2,683,500 Series A-1 5,367,001 Series B 6,588,542 14,693,043 In September and October 2019, Private Augmedix raised $15,271,440 in cash proceeds through issuance of 5,306,910 In February 2020, Private Augmedix raised $499,999 in cash proceeds through issuance of 173,752 allocated to the warrant liability based on an initial fair value of $95,478 with a corresponding amount recorded as a reduction in the carrying amount of the Series B. Private Augmedix incurred issuance costs of $4,017 which were recorded as a reduction of the proceeds. Series B Convertible Preferred Stock Warrants In August 2019, in connection with amending its Sub Agreement (Note 7), the Company issued a warrant to purchase 580,383

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Equity Incentive Plan	9. Equity Incentive Plan At the Effective Time of the Merger, the Company assumed Private Augmedix’s 2013 Equity Incentive Plan (“2013 Plan”). Options granted under the Plan may be incentive stock options (“ISOs”), non -qualified Pursuant to the Merger, the Company adopted the 2020 Equity Incentive Plan (“2020 Plan”) which serves as successor to the 2013 Plan. The 2020 Plan authorizes the award of stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards, cash awards, and stock bonus awards. Certain awards provide for accelerated vesting in the event of a change in control. Options issued may have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the Board of Directors. Vesting generally occurs over a period of not greater than four years. The number of shares reserved for issuance under the 2020 Plan will increase automatically on January The Company recorded share -based Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 General and administrative $ 174 $ 219 $ 391 $ 290 Sales and marketing 16 38 57 52 Research and development 42 30 113 40 Cost of revenues 7 8 62 11 $ 239 $ 295 $ 623 $ 393 No income tax benefits have been recognized in the condensed consolidated statements of operations for stock -based -based The fair value of options is estimated using the Black -Scholes • • • -free • For the six months ended June -Scholes Six Months Ended 2021 2020 Expected term (in years) 5.8 5.7 Expected Volatility 54.5 % 43.0 % Risk-free rate 0.8 % 0.6 % Dividend rate — — The weighted average grant date fair value of stock option awards granted was $1.50 and $0.11 during the six months ended June The following table summarizes stock option activity under the Plan for the six months ended June Number of Weighted- Average Exercise Weighted- Outstanding at December 31, 2020 4,211,857 $ 0.76 8.6 Granted 2,378,915 $ 3.00 Exercised (154,902 ) $ 0.81 Forfeited and expired (69,905 ) $ 1.36 Outstanding at June 30, 2021 6,365,965 $ 1.59 8.40 Exercisable at June 30, 2021 2,939,225 $ 0.93 8.18 Vested and expected to vest at June 30, 2021 5,955,731 $ 1.49 8.60 There were 126,876 options exercised during the six months ended June -based -average Performance and Market-Based Options In March 2021, the Company granted 727,922 stock options to the Chief Executive Officer (“CEO”) under the 2020 Plan with an exercise price of $3.00 per share. The options vest based on the CEO’s continued service in addition to the following terms: • • • The grant date fair value of the options was determined using a Monte Carlo simulation model. The Company’s assumptions for expected volatility, closing price and risk -free -based	9. Equity Incentive Plan At the Effective Time of the Merger, the Company assumed Private Augmedix’s 2013 Equity Incentive Plan (“2013 Plan”). Options granted under the Plan may be incentive stock options (“ISOs”), non -qualified Pursuant to the Merger, the Company adopted the 2020 Equity Incentive Plan (“2020 Plan”) which serves as successor to the 2013 Plan. The 2020 Plan authorizes the award of stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards, cash awards, and stock bonus awards. Certain awards provide for accelerated vesting in the event of a change in control. Options issued may have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the Board of Directors. Vesting generally occurs over a period of not greater than four years. The number of shares reserved for issuance under the 2020 Plan will increase automatically on January The Company recorded share -based Year ended 2020 2019 General and administrative $ 444,495 $ 256,508 Sales and marketing 126,632 69,856 Research and development 65,518 55,921 Cost of revenues 31,427 14,814 $ 668,072 $ 397,099 No income tax benefits have been recognized in the consolidated statements of operations for stock -based -based The fair value of options is estimated using the Black Scholes option pricing model which takes into account inputs such as the exercise price, the value of the underlying ordinary shares at the grant date, expected term, expected volatility, risk free interest rate and dividend yield. The fair value of each grant of options during the year ended December • • • -free • For the years ended December -Scholes -pricing December 31, 2020 2019 Expected term (in years) 5.72 6.4 Expected Volatility 42.9 % 40.5 % Risk-free rate 0.5 % 2.0 % Dividend rate — — The weighted average grant date fair value of stock option awards granted was $0.05 and $0.35 during the years ended December The following table summarizes stock option activity under the Plan for the year ended December Number of Weighted-Average Exercise Weighted- Outstanding at December 31, 2019 2,749,298 $ 0.87 9.0 Granted 2,064,603 0.64 9.3 Exercised (100,059 ) 0.81 Forfeited and expired (501,985 ) 0.83 Outstanding at December 31, 2020 4,211,857 $ 0.76 8.6 Exercisable at December 31, 2020 2,374,630 $ 0.78 8.5 Vested and expected to vest at December 31, 2020 4,211,857 $ 0.76 8.6 The options exercised during the year ended December -based -average

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Operating Leases The Company leases its office facilities in San Francisco, California under non -cancelable -free -line As of June -cancelable (in thousands) 2021 (remaining six months) $ 276 2022 849 2023 874 2024 900 2025 151 Total $ 3,050 Cloud Computing Services In June 2021, the Company entered into a noncancellable three -year -year Legal In the normal course of business, the Company may receive inquiries or become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material adverse effect on the Company’s condensed consolidated interim financial position or results of operations. As a result, no liability related to such claims has been recorded at June Indemnification Agreements From time to time, in the normal course of business, the Company may indemnify other parties when it enters into contractual relationships, including members of the Board of Directors, employees, customers, lessors and parties to other transactions with the Company. The Company may agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or third -party	10. Commitments and Contingencies Operating Leases The Company leases its office facilities in San Francisco, California under non -cancelable -free -line Future minimum rental payments under all non -cancelable Years ending December 31: 2021 $ 340,325 2022 848,602 2023 874,060 2024 900,281 2025 150,779 Thereafter — Total $ 3,114,047 Legal In the normal course of business, the Company may receive inquiries or become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material adverse effect on the Company’s consolidated financial position or results of operations. As a result, no liability related to such claims has been recorded at December Indemnification Agreements From time to time, in the normal course of business, the Company may indemnify other parties when it enters into contractual relationships, including members of the Board of Directors, employees, customers, lessors and parties to other transactions with the Company. The Company may agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or third -party

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. Significant components of the Company’s deferred tax assets for federal income taxes consisted of the following: December 31, 2020 2019 Deferred tax assets Net operating loss carryforwards $ 29,316,923 $ 25,485,398 Fixed assets 814,111 809,015 Accruals and other 247,802 568,119 Research & development credits 448,334 267,325 Share-based compensation 24,036 13,661 Valuation allowance (30,851,206 ) (27,143,518 ) Net deferred tax assets $ — $ — In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company’s net deferred tax assets as of December The Company had net operating loss carryforwards (“NOL”) for federal and state income tax purposes at December December 31, 2020 2019 Combined NOL Carryforwards: Federal $ 117,684,551 $ 103,460,873 State $ 68,800,720 $ 54,408,623 The net operating loss carryforwards generated prior to 2018 begin expiring in 2033 for federal and 2030 for state income tax purposes. Federal and many state net operating losses generated in 2018 and into the future now have an indefinite life. December 31, 2020 2019 Combined Credit Carryforwards: Federal $ 259,521 $ 147,597 State $ 239,004 $ 151,555 The credit carryforwards begin expiring in 2038 for federal tax purposes. The company’s state credits can be carried forward indefinitely. The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows: December 31, 2020 2019 Rate reconciliation: Federal tax benefit at statutory rate (21.0 )% (21.0 )% State tax, net of federal benefit (4.3 )% (5.2 )% Permanent differences 3.9 % 2.4 % Research & development credits (1.2 )% (1.1 )% Foreign rate differential (0.6 )% (0.5 )% Other difference (0.6 )% — % Change in valuation allowance 23.8 % 25.4 % Tax provision — % — % The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company’s 2017 to 2019 tax years remain open and subject to examination; carryforward amounts from all tax years remain subject to adjustment.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Operating Leases In 2015, the Bangladesh subsidiary entered into agreements to rent office facilities under 10 -year	12. Related Party Transactions Operating Leases In 2015, the Bangladesh subsidiary entered into agreements to rent office facilities under 10 -year Convertible Promissory Notes and Series B Convertible Preferred Stock Financing As discussed in Note 7 and Note

Employee benefit plan

Employee benefit plan	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Employee Benefit Plan	12. Employee Benefit Plan The Company has a 401(k) plan to provide defined contribution retirement benefits for all eligible employees. Participants may contribute a portion of their compensation to the 401(k) plan, subject to the limitations under the Internal Revenue Code. The Company’s contributions to the 401(k) plan are at the discretion of the Board of Directors. During the three months ended June	13. Employee Benefit Plan The Company has a 401(k) plan to provide defined contribution retirement benefits for all eligible employees. Participants may contribute a portion of their compensation to the plan, subject to the limitations under the Internal Revenue Code. The Company’s contributions to the plan are at the discretion of the Board of Directors. During the years ended December

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Management has evaluated subsequent events occurring after June Stock Option Grants In July 2021, the Company granted 237,803 stock options with a weighted average exercise price of $4.50.	14. Subsequent Events Listing on the OTCQX Market On March Loan and Security Agreement On March -half Proceeds from the Loan Agreement were used to pay off the note payable and subordinated note payable (Note 7). Issuance costs associated with the Loan Agreements are estimated at $0.2 In connection with the Loan Agreement, the Company issued the Lender warrants to purchase up to 346,500 The Company and Lender also entered into a Co -Investment Stock Option Grants In January and March 2021, the Company granted 540,126 and 1,843,489 stock options, respectively, with a weighted average exercise price of $3.00.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standard Updates (“ASUs”) of the FASB. The accompanying unaudited interim condensed consolidated financial statements include the accounts of Augmedix, Inc. and its wholly owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited and Augmedix Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of June -K	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by ASUs of the FASB. The accompanying consolidated financial statements include the accounts of Augmedix, Inc. and its wholly owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited and Augmedix Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments involve the identification of performance obligations in revenue recognition and the valuation of the warrant liability and stock -based	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments involve the identification of performance obligations in revenue recognition and the valuation of the warrant liability and stock -based
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making
Reverse Stock Split		Reverse Stock Split In March 2019, the Board of Directors approved an amendment of the Company’s Certificate of Incorporation approving a 10:1 reverse stock split on all authorized and outstanding shares of common stock and preferred stock. All references to common stock share, preferred stock share and per share amounts in these consolidated financial statements have been retroactively adjusted to reflect, where applicable, the reverse stock split, as indicated.
Foreign Currency Transactions, Translations and Foreign Operations	Foreign Currency Transactions, Translations and Foreign Operations The functional currency of the Bangladesh and India subsidiaries are the Bangladeshi Taka and Indian Rupee, respectively. All assets and liabilities denominated in each entity’s functional currency are translated into the U.S. dollar using the exchange rate in effect as of the balance sheet dates. Expenses are translated using the weighted average exchange rate for the reporting period. The resulting translation gains and losses are recorded within the unaudited interim condensed consolidated statements of operations and comprehensive loss and as a separate component of stockholders’ (deficit) equity. Foreign currency transaction gains and losses are recorded within other income (expense) in the accompanying unaudited interim condensed consolidated statements of operations and comprehensive loss. Transaction gains and losses were not material for the three and six months ended June Operations outside the United States are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange.	Foreign Currency Transactions, Translations and Foreign Operations The functional currency of the Bangladesh and India subsidiaries are the Bangladeshi Taka and Indian Rupee, respectively. All assets and liabilities denominated in each entity’s functional currency are translated into the U.S. dollar using the exchange rate in effect as of the balance sheet dates. Expenses are translated using the weighted average exchange rate for the reporting period. The resulting translation gains and losses are recorded within the consolidated statements of operations and comprehensive loss and as a separate component of stockholders’ equity (deficit). Foreign currency transaction gains and losses are recorded within other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. Transaction gains and losses were not material for the years ended December Operations outside the United States are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange.
Concentrations of Credit Risk and Major Customers	Concentrations of Credit Risk and Major Customers Financial instruments at June The Company’s cash is deposited with major financial institutions in the United States, Bangladesh and India. At times, deposits in financial institutions located in the United States may be in excess of the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation (FDIC). Cash deposits at foreign financial institutions are not insured by government agencies of Bangladesh and India. To date, the Company has not experienced any losses on its cash deposits. The Company’s accounts receivable are derived from revenue earned from customers located in the United States. Major customers are defined as those generating revenue in excess of 10% of the Company’s annual revenue. The Company had three major customers during the three and six months ended June	Concentrations of Credit Risk and Major Customers Financial instruments at December The Company’s cash is deposited with major financial institutions in the United States, Bangladesh and India. At times, deposits in financial institutions located in the United States may be in excess of the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation (FDIC). Cash deposits at foreign financial institutions are not insured by government agencies of Bangladesh and India. To date, the Company has not experienced any losses on its cash deposits. The Company’s accounts receivable are derived from revenue earned from customers located in the United States. Major customers are defined as those generating revenue in excess of 10% of the Company’s annual revenue. The Company had two major customers during the year ended December and 20% of revenue for the year ended December
Restricted Cash	Restricted Cash Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s credit card facility balances and to collateralize a letter of credit in the name of the Company’s landlord pursuant to a certain operating lease. The following table provides a reconciliation of the components of cash and restricted cash reported in the Company’s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows: June 30, (in thousands) 2021 2020 Cash $ 16,353 $ 3,411 Restricted cash 125 2,000 Restricted cash, non-current 207 — Total cash and restricted cash presented in the condensed consolidated statements of cash flows $ 16,685 $ 5,411	Restricted Cash Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s Note Payable. The following table provides a reconciliation of the components of cash and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows: December 31, 2020 2019 Cash $ 20,762,084 $ 9,603,266 Restricted cash 2,210,902 2,000,119 Total cash and restricted cash presented in the consolidated statements of cash flows $ 22,972,986 $ 11,603,385
Accounts receivable and allowance for doubtful accounts		Accounts receivable and allowance for doubtful accounts Accounts receivable primarily relates to amounts due from customers, which are typically due within 30 to 60 days from invoice date. The Company provides credit to its customers in the normal course of business and maintains allowances for potential credit losses. The Company does not require collateral or other security for accounts receivable. To reduce credit risk with accounts receivable, the Company performs ongoing evaluations of its customers’ financial condition. Historically, such losses have been immaterial and within management’s expectations.
Property and Equipment		Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. The Company depreciates computer hardware, software and equipment using the straight -line -line
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long -lived	Impairment of Long-Lived Assets The Company reviews its long -lived
Fair Value of Financial Instruments		Fair Value of Financial Instruments Certain assets and liabilities of the Company are carried at fair value under GAAP. The Company uses a three -level -based -specific at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with those financial instruments. The three -level Level 1: Level 2: Level 3: An asset or liability’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Convertible Preferred Stock Warrants		Convertible Preferred Stock Warrants Accounting standards require that freestanding warrants and similar instruments, due to settlement features of the financial instruments, should be accounted for as a preferred stock warrant liability even though the underlying shares of capital stock may be classified as equity. Such warrants are measured and recognized at fair value, and subject to re -measurement
Revenue Recognition	Revenue Recognition ASC Topic 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The core principle, involving a five -step The Company derives its revenue through a recurring subscription model. The Company enters into contracts or agreements with its customers with a general initial term of one year. Customers are invoiced in advance and must generally pay an upfront implementation fee. The upfront implementation fee is deferred and recognized over the initial term of the contract and customer prepayments are deferred and included in the accompanying unaudited interim condensed consolidated balance sheets in deferred revenues. Revenues are recognized when the professional services are provided to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company’s revenues are earned from customers located only in the United States. After the initial term, contracts are cancellable by the customer at their discretion with a 90 day notice. The Company determines revenue recognition through the following steps: • • • • • Except for two U.S. state sales tax jurisdictions, applicable taxes, including local, sales, value added tax, etc., are the responsibility of the customer to self -assess The Company also generates revenue from data service projects, which includes projects to complete certain tasks or provide other services to customers. These services represent separate performance obligations which are recognized as revenue as the services are performed.	Revenue Recognition ASC Topic 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The core principle, involving a five -step The Company derives its revenue through a recurring subscription model. The Company enters into contracts or agreements with its customers with a general initial term of one year. Customers are invoiced in advance and must generally pay an upfront implementation fee. The upfront implementation fee is deferred and recognized over the initial term of the contract and customer prepayments are deferred and included in the accompanying consolidated balance sheets in deferred revenues. Revenues are recognized when the professional services are provided to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company’s revenues are earned from customers primarily located in the United States. After the initial term, contracts are cancellable by the customer at their discretion with a 90 day notice. The Company determines revenue recognition through the following steps: • • • • • Except for two U.S. state sales tax jurisdictions, applicable taxes, including local, sales, value added tax, etc., are the responsibility of the customer to self -assess The Company also generates revenue from data service projects, which includes discrete projects to complete certain tasks or provide other services to customers. These services represent separate performance obligations which are recognized as revenue as the services are performed.
Contract Balances and Accounts Receivable	Contract Balances and Accounts Receivable Changes in the contract liability deferred revenue account were as follows for the six months ended June (in thousands) Six Months Ended Year Ended Balance, beginning of period $ 5,439 $ 5,510 Deferral of revenue 10,409 16,412 Recognition of unearned revenue (9,963 ) (16,483 ) Balance, end of period $ 5,885 $ 5,439 Accounts receivable, net from customers was $3.8 Deferred revenue consists of billings or payments received in advance of revenue recognized for the Company’s services, as described above, and is recognized as revenue as earned. As of June	Contract Balances and Accounts Receivable Changes in the contract liability deferred revenue account were as follows for the years ended December Years Ended 2020 2019 Balance, beginning of year $ 5,510,460 $ 4,865,499 Deferral of revenue 16,411,279 14,752,642 Recognition of unearned revenue (16,483,184 ) (14,107,681 ) Balance, end of year $ 5,438,555 $ 5,510,460 Accounts receivable, net from customers was $2,692,540 and $2,290,803 as of December Deferred revenue consists of billings or payments received in advance of revenue recognized for the Company’s services, as described above, and is recognized as revenue as earned. As of December
Customer Deposits		Customer Deposits Customer deposits consists of deposits received by the Company, as required on certain contracts and agreements, which are refundable at the termination of the contract.
Cost of Revenue		Cost of Revenue The Company’s cost of revenue consists primarily of salaries and related expenses, overhead, contract labor and third party services from MDS Vendors, depreciation expense related to the glass equipment and information technology costs incurred directly in the Company’s revenue -generating
Stock-Based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees based on the estimated fair value of the award on the grant date. The fair value of each option award is estimated using either a Black -Scholes -pricing -line Estimating the fair market value of options requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock prior to the Merger (Note 1), the expected life of the options, stock price volatility, the risk -free -condition	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees based on the estimated fair market value of the award on the grant date. The Company uses the Black -Scholes -line -based On January -7 Compensation — Stock Compensation (ASC Topic 718): Improvements to Nonemployee Share -Based Payment Accounting -based -based -7 Estimating the fair market value of options requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock, the expected life of the options, stock price volatility, the risk -free -Scholes -pricing
Research and Development Costs		Research and Development Costs Research and development costs are expensed as incurred and consist primarily of personnel -related
Advertising Costs	Advertising Costs All advertising costs are expensed as incurred and included in sales and marketing expenses. In April 2021, the Company issued 120,000 -year	Advertising Costs All advertising costs are expensed as incurred and included in sales and marketing expenses. Advertising expenses incurred by the Company were $155,835 and $51,919 for the years ended December
Comprehensive Loss		Comprehensive Loss The Company reports comprehensive loss, which includes the Company’s net loss as well as changes in equity from non -stockholder
Income Taxes		Income Taxes Income taxes are accounted for under the asset and liability method as required by FASB ASC Topic 740, Income Taxes FASB ASC Subtopic 740 -10 Accounting for Uncertainty of Income Taxes -10 -10
Net Loss Per Share	Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the six months ended June The following potentially dilutive securities have been excluded from the computation of diluted weighted -average -dilutive June 30, June 30, Convertible preferred stock — 14,812,795 Convertible preferred stock warrants — 2,767,836 Common stock warrants 3,333,791 5,585 Stock options 6,365,965 4,465,548 9,699,756 22,051,764	Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the years ended December The following potentially dilutive securities have been excluded from the computation of diluted weighted -average -dilutive December 31, 2020 2019 Convertible preferred stock — 14,639,043 Convertible preferred stock warrants — 2,710,498 Common stock warrants 2,991,499 5,585 Stock options 4,211,857 2,749,298 7,203,356 20,104,424
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASC Topic 842, Leases, (“Topic 842”). This standard requires all entities that lease assets with terms of more than 12 -05 In August 2020, the FASB issued ASU Update No. 2020 -06 -20 -40 In June 2016, the FASB issued ASU 2016 -13	Recent Accounting Pronouncements In February 2016, the FASB issued ASC Topic 842, Leases, -05 In August 2016, the FASB issued ASU No. 2016 -15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments -15 In August 2018, the FASB issued ASU 2018 -13 Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurements In August 2020, the FASB issued ASC Update No. 2020 -06 Debt — Debt with Conversion and Other Options (Subtopic 470 -20 ) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815 -40 ): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In June 2016, the FASB issued ASU 2016 -13 Financial Instruments — Credit Losses,

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of reconciliation of the components of cash and restricted cash	June 30, (in thousands) 2021 2020 Cash $ 16,353 $ 3,411 Restricted cash 125 2,000 Restricted cash, non-current 207 — Total cash and restricted cash presented in the condensed consolidated statements of cash flows $ 16,685 $ 5,411	December 31, 2020 2019 Cash $ 20,762,084 $ 9,603,266 Restricted cash 2,210,902 2,000,119 Total cash and restricted cash presented in the consolidated statements of cash flows $ 22,972,986 $ 11,603,385
Schedule of liability deferred revenue	(in thousands) Six Months Ended Year Ended Balance, beginning of period $ 5,439 $ 5,510 Deferral of revenue 10,409 16,412 Recognition of unearned revenue (9,963 ) (16,483 ) Balance, end of period $ 5,885 $ 5,439	Years Ended 2020 2019 Balance, beginning of year $ 5,510,460 $ 4,865,499 Deferral of revenue 16,411,279 14,752,642 Recognition of unearned revenue (16,483,184 ) (14,107,681 ) Balance, end of year $ 5,438,555 $ 5,510,460
Schedule of diluted weighted-average shares of common stock outstanding	June 30, June 30, Convertible preferred stock — 14,812,795 Convertible preferred stock warrants — 2,767,836 Common stock warrants 3,333,791 5,585 Stock options 6,365,965 4,465,548 9,699,756 22,051,764	December 31, 2020 2019 Convertible preferred stock — 14,639,043 Convertible preferred stock warrants — 2,710,498 Common stock warrants 2,991,499 5,585 Stock options 4,211,857 2,749,298 7,203,356 20,104,424

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	December 31, 2020 (Level 1) (Level 2) (Level 3) Liabilities Preferred stock warrant liability $ — $ — $ — December 31, 2019 (Level 1) (Level 2) (Level 3) Liabilities Preferred stock warrant liability $ — $ — $ 4,391,372
Schedule of significant weighted-average assumptions	October 5, December 31, 2020 2019 Risk-free interest rate 0.7 % 1.9 % Remaining contractual life of warrant (years) 8.9 9.7 Expected volatility 57.8 % 50.9 % Annual dividend yield 0 % 0 % Fair value of Series B convertible preferred stock $ 1.26 $ 1.14
Schedule of Series B preferred stock warrant liability measured at fair value recurring basis using significant unobservable inputs	Balance, January 1, 2019 $ 328,559 Issuance of warrants in connection with Series B financing 3,991,178 Change in fair value recorded as other expense 71,635 Balance, December 31, 2019 4,391,372 Issuance of warrants in connection with Series B financing 95,478 Change in fair value recorded as other expense 743,837 Reclassification to equity (5,230,687 ) Balance, December 31, 2020 $ —

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	(in thousands) June 30, December 31, 2020 Computer hardware, software and equipment $ 5,893 $ 5,557 Leasehold improvements 2,184 2,186 Furniture and fixtures 272 271 8,349 8,014 Less: accumulated depreciation (7,385 ) (7,022 ) Property and equipment, net $ 964 $ 992	December 31, 2020 2019 Computer hardware, software and equipment $ 5,557,034 $ 5,039,545 Leasehold improvements 2,186,239 2,072,006 Furniture and fixtures 270,943 262,865 8,014,216 7,374,416 Less: accumulated depreciation and amortization (7,021,842 ) (6,161,390 ) $ 992,374 $ 1,213,026

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of accrued expenses and other current liabilities	(in thousands) June 30, December 31, Accrued compensation $ 1,556 $ 1,711 Accrued other 466 612 Accrued vendor partner liabilities 627 559 Deferred rent — 21 Accrued professional fees 125 151 Accrued VAT and other taxes 52 55 $ 2,826 $ 3,109	December 31, 2020 2019 Accrued compensation $ 1,711,377 $ 1,196,723 Accrued other 611,947 530,924 Accrued vendor partner liabilities 559,478 769,351 Deferred rent 20,877 210,010 Accrued professional fees 150,859 36,227 Accrued VAT and other taxes 54,755 23,013 $ 3,109,293 $ 2,766,248

Debt (Tables)

Debt (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of future minimum payments under the sub agreement	(in thousands) 2021 (remaining six months) $ — 2022 1,500 2023 6,000 2024 6,000 2025 1,500 15,000 End of term charge 1,125 16,125 Less unamortized debt discount (1,596 ) Loan Agreement borrowing net of discount 14,529 Less current portion — Loan Agreement borrowings, non-current portion $ 14,529	Years ending December 31: 2021 $ 3,719,265 2022 4,190,960 2023 1,511,938 9,422,163 End of term charge 650,000 10,072,163 Less unamortized debt discount (194,816 ) Sub agreement borrowing net of discount 9,877,347 Less current portion (3,719,265 ) Sub agreement borrowings, non-current portion $ 6,158,082

Common Stock, Preferred Stock_2

Common Stock, Preferred Stock and Convertible Preferred Stock (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of warrants outstanding to acquire shares of its common stock	Expiration Date Shares of common stock issuance Exercise June 11, 2025 234 $ 96.24 November 13, 2025 218,078 $ 3.00 July 28, 2027 91 $ 106.17 August 28, 2028 1,052 $ 39.76 September 2, 2029 2,767,836 $ 2.88 Earlier of March 24, 2031 and the third anniversary of the Company’s listing on Nasdaq 346,500 $ 3.00 3,333,791	Expiration Date Shares of common stock issuance upon exercise of warrants Exercise August 7, 2024 4,208 $ 0.86 June 11, 2025 234 $ 96.24 November 13, 2025 218,078 $ 3.00 July 28, 2027 91 $ 106.17 August 28, 2028 1,052 $ 39.76 September 2, 2029 2,767,836 $ 2.88 2,991,499
Schedule of convertible preferred stock shares outstanding		Shares Issued and Outstanding Series A 2,683,500 Series A-1 5,367,001 Series B 6,588,542 14,693,043

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of share-based compensation expense	Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 General and administrative $ 174 $ 219 $ 391 $ 290 Sales and marketing 16 38 57 52 Research and development 42 30 113 40 Cost of revenues 7 8 62 11 $ 239 $ 295 $ 623 $ 393	Year ended 2020 2019 General and administrative $ 444,495 $ 256,508 Sales and marketing 126,632 69,856 Research and development 65,518 55,921 Cost of revenues 31,427 14,814 $ 668,072 $ 397,099
Schedule of fair value of option grants weighted average assumptions	Six Months Ended 2021 2020 Expected term (in years) 5.8 5.7 Expected Volatility 54.5 % 43.0 % Risk-free rate 0.8 % 0.6 % Dividend rate — —	December 31, 2020 2019 Expected term (in years) 5.72 6.4 Expected Volatility 42.9 % 40.5 % Risk-free rate 0.5 % 2.0 % Dividend rate — —
Schedule of stock option activity	Number of Weighted- Average Exercise Weighted- Outstanding at December 31, 2020 4,211,857 $ 0.76 8.6 Granted 2,378,915 $ 3.00 Exercised (154,902 ) $ 0.81 Forfeited and expired (69,905 ) $ 1.36 Outstanding at June 30, 2021 6,365,965 $ 1.59 8.40 Exercisable at June 30, 2021 2,939,225 $ 0.93 8.18 Vested and expected to vest at June 30, 2021 5,955,731 $ 1.49 8.60	Number of Weighted-Average Exercise Weighted- Outstanding at December 31, 2019 2,749,298 $ 0.87 9.0 Granted 2,064,603 0.64 9.3 Exercised (100,059 ) 0.81 Forfeited and expired (501,985 ) 0.83 Outstanding at December 31, 2020 4,211,857 $ 0.76 8.6 Exercisable at December 31, 2020 2,374,630 $ 0.78 8.5 Vested and expected to vest at December 31, 2020 4,211,857 $ 0.76 8.6

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum rental payments under all non-cancelable operating leases	(in thousands) 2021 (remaining six months) $ 276 2022 849 2023 874 2024 900 2025 151 Total $ 3,050	Years ending December 31: 2021 $ 340,325 2022 848,602 2023 874,060 2024 900,281 2025 150,779 Thereafter — Total $ 3,114,047

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets for federal income taxes	December 31, 2020 2019 Deferred tax assets Net operating loss carryforwards $ 29,316,923 $ 25,485,398 Fixed assets 814,111 809,015 Accruals and other 247,802 568,119 Research & development credits 448,334 267,325 Share-based compensation 24,036 13,661 Valuation allowance (30,851,206 ) (27,143,518 ) Net deferred tax assets $ — $ —
Schedule of net operating loss carryforwards (“NOL”) for federal and state income tax	December 31, 2020 2019 Combined NOL Carryforwards: Federal $ 117,684,551 $ 103,460,873 State $ 68,800,720 $ 54,408,623
Schedule of net operating loss carryforwards	December 31, 2020 2019 Combined Credit Carryforwards: Federal $ 259,521 $ 147,597 State $ 239,004 $ 151,555
Schedule of reconciliation of income tax	December 31, 2020 2019 Rate reconciliation: Federal tax benefit at statutory rate (21.0 )% (21.0 )% State tax, net of federal benefit (4.3 )% (5.2 )% Permanent differences 3.9 % 2.4 % Research & development credits (1.2 )% (1.1 )% Foreign rate differential (0.6 )% (0.5 )% Other difference (0.6 )% — % Change in valuation allowance 23.8 % 25.4 % Tax provision — % — %

Organization and Nature of Bu_2

Organization and Nature of Business (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization and Nature of Business (Details) [Line Items]
Common stock value	$ 3,000		$ 3,000		$ 3,000	$ 83
Additional paid-in capital amount	$ 88,773,000		$ 88,773,000		$ 87,051,000	$ 3,174,102
Loss per share adjusted price (in Dollars per share)	$ (0.17)	$ (3.54)	$ (0.35)	$ (9.21)	$ (2.22)	$ (22.24)
Description of substantial going concern					the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.
Net losses	$ 4,600,000	$ 3,000,000	$ 9,500,000	$ 7,700,000	$ 15,600,000	$ 18,500,000
Accumulated deficit	$ 93,400,000		$ 93,400,000		$ 83,900,000
Common share [Member]
Organization and Nature of Business (Details) [Line Items]
Description of conversion ratio					At the Effective Time, each of Private Augmedix’s shares of Series B convertible preferred stock and common stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive (a) 0.420864013 shares of the Company’s common stock (the “Common Share Conversion Ratio”) (in the case of shares held by accredited investors) or (b) $3.00 multiplied by the Common Share Conversion Ratio (in the case of shares held by unaccredited investors and those with an entitlement to shares of Private Augmedix’s capital stock).
Price of conversion ratio (in Dollars per share)					$ 3
Maximum [Member]
Organization and Nature of Business (Details) [Line Items]
Common stock value						198
Additional paid-in capital amount						$ 3,174,102
Loss per share adjusted price (in Dollars per share)						$ 22.24
Minimum [Member]
Organization and Nature of Business (Details) [Line Items]
Common stock value						$ 83
Additional paid-in capital amount						$ 3,173,987
Loss per share adjusted price (in Dollars per share)						$ 9.36

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2021USD ($)shares	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Number of segment						1
Number of customers		3	2	3	2	2	2
Accounts receiveble from customers (in Dollars)						$ 715,563	$ 892,027
Property and equipment estimated useful lives, description						The Company depreciates computer hardware, software and equipment using the straight-line method over their estimated useful lives, ranging from one to three years. The Company depreciates furniture and fixtures using the straight-line method over their estimated useful lives, ranging from five to seven years.
Accounts receivable, net (in Dollars)		$ 3,800,000		$ 3,800,000		$ 2,692,540	2,290,803
Recognition of deferred revenue (in Dollars)						5,438,555
Advertising expenses (in Dollars)		200,000	$ 23,000	$ 400,000	$ 47,000	$ 155,835	$ 51,919
Annual revenue				10.00%
Recognize of remaining performance obligation (in Dollars)				$ 5,900,000
Common stock shares issue (in Shares) | shares	120,000
Fair value (in Dollars)	$ 600,000
Unamortized advertising costs (in Dollars)		500,000		500,000
Customer One [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Accounts receiveble from customers (in Dollars)		100,000	800,000	100,000	800,000
Customer Two [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Accounts receiveble from customers (in Dollars)		1,100,000	$ 600,000	1,100,000	$ 600,000
Customer Three [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Accounts receiveble from customers (in Dollars)		$ 300,000		$ 300,000
Revenues [Member] | Major Customers [Member] | Revenue Benchmark [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage						10.00%
Revenues [Member] | Customer One [Member] | Revenue Benchmark [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage							28.00%
Sales Revenue [Member] | Customer One [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		24.00%	28.00%	26.00%	27.00%
Sales Revenue [Member] | Customer One [Member] | Revenue Benchmark [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage						26.00%
Sales Revenue [Member] | Customer Two [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		23.00%	18.00%	22.00%	19.00%
Sales Revenue [Member] | Customer Two [Member] | Revenue Benchmark [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage						20.00%	17.00%
Sales Revenue [Member] | Customer Three [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		11.00%		11.00%

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the components of cash and restricted cash - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Schedule of reconciliation of the components of cash and restricted cash [Abstract]
Cash	$ 16,353,000	$ 20,762,084	$ 3,411,000	$ 9,603,266
Restricted cash	125,000	2,210,902	2,000,000	2,000,119
Total cash and restricted cash presented in the consolidated statements of cash flows	$ 16,685,000	$ 22,972,986	$ 5,411,000	$ 11,603,385

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of liability deferred revenue - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of liability deferred revenue [Abstract]
Balance, beginning of year	$ 5,510,460	$ 4,865,499
Deferral of revenue	16,411,279	14,752,642
Recognition of unearned revenue	(16,483,184)	(14,107,681)
Balance, end of year	$ 5,438,555	$ 5,510,460

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding	9,699,756	22,051,764	7,203,356	20,104,424
Stock options [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding	6,365,965	4,465,548	4,211,857	2,749,298
Convertible preferred stock [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding				14,639,043
Convertible preferred stock warrants [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding				2,710,498
Common stock warrants [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding	3,333,791	5,585	2,991,499	5,585

Malo Holdings Corporation Mer_2

Malo Holdings Corporation Merger (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Business Combinations [Abstract]
Cash	$ 4,000	$ 4,000
Payables and accruals	56,000	56,000
Closing amount	50,000	50,000
Transaction costs	$ 800,000	$ 753,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Subordinated note payable [Member]
Fair Value Measurements (Details) [Line Items]
Financial instruments fair value	$ 16,100,000	$ 10,600,000
Fair value carrying value	14,500,000	10,072,163
PPP Loan [Member]
Fair Value Measurements (Details) [Line Items]
Financial instruments fair value	2,000,000	1,900,000
Fair value carrying value	$ 2,200,000	$ 2,180,300

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis - USD ($)	Dec. 31, 2020	Dec. 31, 2019
(Level 1) [Member]
Liabilities
Preferred stock warrant liability
(Level 2) [Member]
Liabilities
Preferred stock warrant liability
(Level 3) [Member]
Liabilities
Preferred stock warrant liability		$ 4,391,372

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of significant weighted-average assumptions - $ / shares	Oct. 05, 2020	Dec. 31, 2019
Schedule of significant weighted-average assumptions [Abstract]
Risk-free interest rate	0.70%	1.90%
Remaining contractual life of warrant (years)	8 years 10 months 24 days	9 years 8 months 12 days
Expected volatility	57.80%	50.90%
Annual dividend yield	0.00%	0.00%
Fair value of Series B convertible preferred stock (in Dollars per share)	$ 1.26	$ 1.14

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of Series B preferred stock warrant liability measured at fair value recurring basis using significant unobservable inputs - (Level 3) [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 4,391,372	$ 328,559
Issuance of warrants in connection with Series B financing	95,478	3,991,178
Change in fair value recorded as other expense	743,837	71,635
Reclassification to equity	(5,230,687)
Ending balance		$ 4,391,372

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 200,000	$ 200,000	$ 400,000	$ 400,000	$ 867,000	$ 949,006

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 8,014,216	$ 7,374,416	$ 8,349,000
Less: accumulated depreciation and amortization	(7,021,842)	(6,161,390)
Property and equipment, net	992,374	1,213,026
Computer hardware, software and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,557,034	5,039,545	5,893,000
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,186,239	2,072,006	2,184,000
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 270,943	$ 262,865	$ 272,000

Accrued expenses and other cu_3

Accrued expenses and other current liabilities (Details) - Schedule of accrued expenses and other current liabilities - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of accrued expenses and other current liabilities [Abstract]
Accrued compensation	$ 1,556,000	$ 1,711,377	$ 1,196,723
Accrued other	466,000	611,947	530,924
Accrued vendor partner liabilities	627,000	559,478	769,351
Deferred rent		20,877	210,010
Accrued professional fees	125,000	150,859	36,227
Accrued VAT and other taxes	52,000	54,755	23,013
Accrued expenses and other current liabilities	$ 2,826,000	$ 3,109,293	$ 2,766,248

Debt (Details)

Debt (Details) - USD ($)

Apr. 11, 2020

Mar. 25, 2021

Nov. 30, 2020

Feb. 29, 2020

Sep. 30, 2019

Aug. 31, 2019

Oct. 31, 2018

May 31, 2018

May 31, 2017

Jun. 30, 2015

Mar. 31, 2021

Mar. 31, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Dec. 31, 2019

Debt (Details) [Line Items]

Maintain minimum amount

$ 2,000,000

$ 2,000,000

Outstanding balance of note payable

$ 2,893,667

$ 2,893,667

Purchase of shares (in Shares)

1,666,667

Exercisable and expire

In addition, the Company issued warrants to purchase up to 378,836 shares of Series B convertible preferred stock at a price of $2.88 per share with an initial aggregate fair value of $709,962 which are immediately exercisable and expire in September 2029.

The warrants have an exercise price of $96.24 per share and $106.17 per share, are immediately exercisable and expire in June 2025 and July 2027, respectively.

The warrant had an exercise price of $148.10 per share, was immediately exercisable and was to expire in July 2027.

Warrant exercise price (in Dollars per share)

$ 2.88

Maturity date description

the Company amended the Sub Agreement (“Amended Sub Agreement”) to extend the interest-only period through December 2020 and the maturity date to April 2023. Following the interest-only period, the Amended Sub Agreement requires 28 equal payments of principal and interest through March 2023, and a final lump sum payment of outstanding principal and interest at maturity.

Pursuant to the Sub Agreement, a final payment of $0.7 million was payable at the maturity date in April 2023.

Pursuant to the Sub Agreement, a final payment of $650,000 is payable at the maturity date in April 2023.

Amortized discount

$ 34,000

$ 36,000

$ 105,739

327,138

Unamortized discount

194,816

300,555

Fair value of warrant

$ 95,478

$ 186,000

743,837

71,635

Cash proceeds

$ 500,000

$ 3,303,535

Maturity date

The notes accrued simple interest of 6% per year and, if not converted, were to mature in January 2020.

Interest expense

$ 1,078,769

200,000

Outstanding balance

2,180,000

2,180,000

Notes payable

$ 2,900,000

Unamortized discount

$ 200,000

Investment agreement, description

The Company and Lender also entered into a Co-Investment Agreement, which grants to the Lender and its affiliates a right to purchase in the Company’s future private equity financings up to a total $3.0 million (if the Company only draws the first tranche) or $3.4 million (if the Company draws the second tranche) at the same per share purchase price and terms as other investors in such private equity financings.

Security Agreement [Member]

Debt (Details) [Line Items]

Borrowings amount

$ 3,500,000

Interest rate

3.62%

5.25%

Description of debt

The Agreement initially required monthly interest- only payments through December 2016, followed by 30 equal payments of principal and interest beginning January 2017 through its maturity in June 2019. However, the Agreement was amended multiple times, most recently in December 2020 and January 2021 to change the principal payment from a lump sum payment at December 31, 2020 to a 12-month amortization starting January 31, 2021 and be fully repaid on December 31, 2021. The Company must maintain at least $2,000,000 in an account with and under the control of the commercial bank, that reduces in line with the loan balance once the loan balance declines below $2,000,000.

Sub Agreement [Member]

Debt (Details) [Line Items]

Borrowings amount

$ 10,000,000

Interest rate

12.00%

12.00%

12.00%

Purchase of shares (in Shares)

3,376

Warrant exercise price (in Dollars per share)

$ 148.10

Final payment

$ 700,000

$ 650,000

Legal cost

300,000

279,757

Amortized discount

1,200,000

1,195,012

Fair value of warrant

$ 265,255

Convertible Promissory Notes [Member]

Debt (Details) [Line Items]

Cash proceeds

$ 3,303,535

Gross proceeds

$ 14,700,000

Percentage of conversion price

90.00%

PPP Loan [Member]

Debt (Details) [Line Items]

Interest rate

1.00%

Description of debt

The PPP Loan matures in two years and bears interest at a rate of 1% per year, with all payments deferred through the six-month anniversary of the date of the PPP Loan. Principal plus accrued unpaid interest is to be paid in one payment two years after the date of this note and may be prepaid by the Company at any time prior to maturity without penalty. The Company may apply for forgiveness of amounts due under the PPP Loan, with the amount of potential loan forgiveness to be calculated in accordance with the requirements of the CARES Act based on payroll costs, any mortgage interest payments, any covered rent payments and any covered utilities payments during the 8-24 week period after the origination date of the Loan.

Principal amount

$ 2,180,300

Outstanding balance

$ 2,200,000

2,180,300

Commercial Bank [Member]

Debt (Details) [Line Items]

Maintain minimum amount

$ 2,000,000

$ 2,000,000

Purchase of shares (in Shares)

234

Warrant exercise price (in Dollars per share)

$ 96.24

Series A-2 [Member]

Debt (Details) [Line Items]

Purchase of shares (in Shares)

3,376

Series B convertible preferred stock [Member]

Debt (Details) [Line Items]

Purchase of shares (in Shares)

580,383

12,576

580,383

Warrant exercise price (in Dollars per share)

$ 2.88

Fair value of warrant

709,962

Principal amount

$ 15,748

Converted shares (in Shares)

1,281,631

Price per share (in Dollars per share)

$ 2.88

Series A-1 convertible preferred stock [Member]

Debt (Details) [Line Items]

Purchase of shares (in Shares)

100,712

Warrant exercise price (in Dollars per share)

$ 4.76

Loan and Security Agreement [Member]

Debt (Details) [Line Items]

Description of debt

the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Eastward Fund Management, LLC, as the lender (“Lender”) to establish a loan facility which provides for borrowings in the aggregate principal amount of up to $17.0 million, which are available to be drawn in two tranches. The first tranche of $15.0 million was funded on March 31, 2021. The second tranche of $2.0 million is available, at the Company’s request, between October 30, 2021 and November 30, 2021, provided the Company achieves at least $6,000,000 in revenue and a maximum EBITDA loss of $4,800,000 in each case for the third fiscal quarter of 2021. Outstanding borrowings under the Loan Agreement are secured by a first priority lien on substantially all of the personal property assets of the Company, including the Company’s intellectual property. The Company is required to pay only interest during the first 18 months after funding of the tranche and thereafter, the Company shall repay such loan amount in 30 consecutive equal monthly installments of principal plus accrued interest. The loan facility bears an annual interest rate of the prime rate as published in the Wall Street Journal, subject to a floor 3.25%, plus 8.75%. On the final repayment date, Company is also obligated to pay a final payment fee equal to seven and one-half percent (7.5%) of the amount of the applicable advance.

In connection with the Loan Agreement, the Company issued the Lender warrants with a fair value of $0.4 million, which was recorded as a discount to the loan, to purchase up to 346,500 shares (increasing to 392,700 shares upon funding of the second tranche) of common stock that were immediately vested upon funding with an exercise price of $3.00 per share and a term of the earlier of i) March 24, 2031 and ii) the third anniversary of the Company’s listing on Nasdaq. The warrants also provide that any shares issued pursuant to the warrants are entitled to the registration rights afforded to holders of the Company’s stock, all as set forth in those certain outstanding Registration Rights Agreement dated as of October 5, 2020.The Company recorded the final payment of $1.1 million as both a discount and an increase to the principal amount of the debt. The Company also capitalized certain lender and legal costs associated with the Loan Agreement totaling $0.2 million, which were recorded as a discount to the loan. The aggregate discount of $1.8 million is being amortized to interest expense over the repayment term of the Loan and Security Agreement. The Company amortized $0.1 million and $0.2 million of the discount to interest expense during the three months and six months ended June 30, 2021, respectively. At June 30, 2021, the remaining unamortized discount was $1.6 million.

Warrant [Member]

Debt (Details) [Line Items]

Purchase of shares (in Shares)

91

Warrant exercise price (in Dollars per share)

$ 106.17

Fair value of warrant

$ 100,000

Common stock [Member]

Debt (Details) [Line Items]

Purchase of shares (in Shares)

666,667

10,000,000

Common stock [Member] | Series B convertible preferred stock [Member]

Debt (Details) [Line Items]

Purchase of shares (in Shares)

378,836

378,836

Price per share (in Dollars per share)

$ 2.88

Prime Rate [Member] | Security Agreement [Member]

Debt (Details) [Line Items]

Interest rate

0.50%

0.50%

Debt (Details) - Schedule of fu

Debt (Details) - Schedule of future minimum payments under the sub agreement	Dec. 31, 2020USD ($)
Schedule of future minimum payments under the sub agreement [Abstract]
2021	$ 3,719,265
2022	4,190,960
2023	1,511,938
Total	9,422,163
End of term charge	650,000
Subordinated note payable	10,072,163
Less unamortized debt discount	(194,816)
Sub agreement borrowing net of discount	9,877,347
Less current portion	(3,719,265)
Sub agreement borrowings, non-current portion	$ 6,158,082

Common Stock, Preferred Stock_3

Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - USD ($)	1 Months Ended				2 Months Ended	6 Months Ended		12 Months Ended
	Nov. 30, 2020	Feb. 29, 2020	Aug. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Common stock, shares authorized						500,000,000		500,000,000	500,000,000
Common stock par value (in Dollars per share)						$ 0.0001		$ 0.0001	$ 0.0001
Lieu of issuing shares (in Dollars)						$ 7,000		$ (52,044)
Shares of common stock								1,666,667
Warrants to purchase shares					2,130,115
Exercisable and expire		In February 2020, Private Augmedix raised $0.5 million in cash proceeds through issuance of 173,752 shares of Series B to certain existing shareholders and warrants to purchase up to 57,338 shares of Series B at a price of $2.88 per share, are immediately exercisable and expire in September 2029.	The warrants have an exercise price of $39.76 per share and $0.86 per share, are immediately exercisable and expire in August 2028 and August 2024, respectively.
Preferred stock, shares authorized						10,000,000		10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)						$ 0.0001		$ 0.0001	$ 0.0001
Issued shares of convertible preferred stock						14,804,274		14,804,274
Fair value of warrant liability (in Dollars)		$ 95,478					$ 186,000	$ 743,837	$ 71,635
Issuance costs (in Dollars)								$ 52,893
Exercisable and expire			At the Effective Time of the Merger, the warrants to purchase shares of Series B were converted to warrants to purchase 2,767,836 shares of common stock at a price of $2.88 per share, are immediately exercisable and expire in September 2029.
Sub Agreement [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Warrants to purchase shares		2,767,836
Exercise price per share (in Dollars per share)		$ 2.88
Private Placement [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Shares of common stock								8,472,188
Purchase price (in Dollars per share)								$ 3
Aggregate gross proceeds (in Dollars)								$ 25,400,000
Issuance costs (in Dollars)	$ 160,000							$ 3,000,000
Warrants to purchase shares	53,333							164,745
Exercise price per share (in Dollars per share)	$ 3							$ 3
Un accredited Investor [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Lieu of issuing shares (in Dollars)								$ 555,174
Lieu of issuing shares (in Dollars)						$ 600,000
Majority Shareholder [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Lieu of issuing shares (in Dollars)								$ 31,527
Non-employee [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Warrants to purchase shares			4,208	1,052
Exercise price per share (in Dollars per share)			$ 0.86	$ 39.76
Series B Preferred Stock [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Warrants to purchase shares		57,338			1,751,279
Exercise price per share (in Dollars per share)		$ 2.88
Cash proceeds (in Dollars)		$ 499,999			$ 15,271,440
Issued shares of convertible preferred stock		173,752			5,306,910			1,281,631
Fair value of warrant liability (in Dollars)								$ 3,281,216
Issuance costs (in Dollars)		$ 4,017
Issuance costs (in Dollars)		$ 4,000
Series B Preferred Stock [Member] | Sub Agreement [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Warrants to purchase shares		57,338	580,383		57,338	580,383				2,130,115
Series B Preferred Stock [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Exercise price per share (in Dollars per share)					$ 2.88
Common Stock [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Common stock share issued						2,166,667		2,166,667
Lieu of issuing shares (in Dollars)								$ 217
Shares of common stock	666,667							10,000,000
Aggregate gross proceeds (in Dollars)	$ 2,000,000
Issued shares of convertible preferred stock
Warrant [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]
Shares of common stock				91
Exercisable and expire		In February 2020, Private Augmedix raised $499,999 in cash proceeds through issuance of 173,752 shares of Series B to certain existing shareholders and warrants to purchase up to 57,338 shares of Series B at a price of $2.88 per share, are immediately exercisable and expire in September 2029.
Fair value of warrant liability (in Dollars)		$ 100,000

Common Stock, Preferred Stock_4

Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of warrants outstanding to acquire shares of its common stock - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Shares of common stock issuance upon exercise of warrants	3,333,791	2,991,499
August 7, 2024 [Member]
Class of Warrant or Right [Line Items]
Expiration Date		Aug. 7, 2024
Shares of common stock issuance upon exercise of warrants		4,208
Exercise Price Per Warrant (in Dollars per share)		$ 0.86
June 11, 2025 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Jun. 11, 2025	Jun. 11, 2025
Shares of common stock issuance upon exercise of warrants	234	234
Exercise Price Per Warrant (in Dollars per share)	$ 96.24	$ 96.24
November 13, 2025 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Nov. 13, 2025	Nov. 13, 2025
Shares of common stock issuance upon exercise of warrants	218,078	218,078
Exercise Price Per Warrant (in Dollars per share)	$ 3	$ 3
July 28, 2027 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Jul. 28, 2027	Jul. 28, 2027
Shares of common stock issuance upon exercise of warrants	91	91
Exercise Price Per Warrant (in Dollars per share)	$ 106.17	$ 106.17
August 28, 2028 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Aug. 28, 2028	Aug. 28, 2028
Shares of common stock issuance upon exercise of warrants	1,052	1,052
Exercise Price Per Warrant (in Dollars per share)	$ 39.76	$ 39.76
September 2, 2029 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Sep. 2, 2029	Sep. 2, 2029
Shares of common stock issuance upon exercise of warrants	2,767,836	2,767,836
Exercise Price Per Warrant (in Dollars per share)	$ 2.88	$ 2.88

Common Stock, Preferred Stock_5

Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of convertible preferred stock shares outstanding	Dec. 31, 2019shares
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of convertible preferred stock shares outstanding [Line Items]
Shares Issued and Outstanding	14,693,043
Series A [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of convertible preferred stock shares outstanding [Line Items]
Shares Issued and Outstanding	2,683,500
Series A-1 [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of convertible preferred stock shares outstanding [Line Items]
Shares Issued and Outstanding	5,367,001
Series B [Member]
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of convertible preferred stock shares outstanding [Line Items]
Shares Issued and Outstanding	6,588,542

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - USD ($)	Jan. 02, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Equity Incentive Plan (Details) [Line Items]
Shares remained available for grant (in Shares)		2,300,000
Weighted average grant date fair value of stock option awards granted (in Dollars per share)		$ 1.50	$ 0.11	$ 0.05	$ 0.35
Intrinsic value options exercised		$ 500,000		$ 211,019
Intrinsic value options outstanding		27,100,000		9,438,695
Intrinsic value options exercisable		$ 14,500,000		5,270,372
Stock-based compensation for option granted and outstanding				$ 710,852
Remaining weighted average requisite service period				1 year
Options exercised (in Shares)		126,876
Weighted average requisite service period		2 years 7 months 6 days
Stock based compensation for stock options, description		the Company granted 727,922 stock options to the Chief Executive Officer (“CEO”) under the 2020 Plan with an exercise price of $3.00 per share. The options vest based on the CEO’s continued service in addition to the following terms:• 317,688 options vest in full when the closing price of the Company’s common stock reaches or exceeds $9.00 per share for a minimum of 20 consecutive trading days. These options expire on March 3, 2031.• 46,273 options vest in full when the closing price of the Company’s common stock reaches or exceeds $9.00 per share for 20 out of 30 trading days after the Company becomes listed on the New York Stock Exchange or Nasdaq. These options expire on March 22, 2026.• 363,961 options vest in full when the closing price of the Company’s common stock reaches or exceeds $13.50 per share for 20 out of 30 trading days after the Company becomes listed on the New York Stock Exchange or Nasdaq. These options expire on March 22, 2026.
Share based compensation fair value, description		The Company’s assumptions for expected volatility, closing price and risk-free rate were 50.0%, $3.00 and 0.77%, respectively. The aggregate estimated fair value of the options was $0.4 million. The Company recognized $10,000 and $16,000 in share-based expense for the three and six months ended June 30, 2021, respectively. As of June 30, 2021, there was $0.2 million of unrecognized compensation costs which the Company plans to recognize over a weighted average period of 2.5 years. Also, as of June 30, 2021 there is an additional $0.2 million of unrecognized compensation cost which the Company will begin to recognize when it becomes probable the Company will be listed on either the New York Stock Exchange or Nasdaq.
2020 Equity incentive Plan [Member]
Equity Incentive Plan (Details) [Line Items]
Options contractual life		10 years		10 years
Vesting period		4 years		4 years
Number of shares equal percentage				5.00%
Shares remained available for grant (in Shares)		33,783		600,102
Number of shares equal percentage	5.00%
Common stock issuance (in Shares)		643,761

Equity Incentive Plan (Detail_2

Equity Incentive Plan (Details) - Schedule of share-based compensation expense - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 239	$ 295	$ 623	$ 393	$ 668,072	$ 397,099
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	174	219	391	290	444,495	256,508
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	16	38	57	52	126,632	69,856
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	42	30	113	40	65,518	55,921
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 7	$ 8	$ 62	$ 11	$ 31,427	$ 14,814

Equity Incentive Plan (Detail_3

Equity Incentive Plan (Details) - Schedule of fair value of option grants weighted average assumptions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Schedule of fair value of option grants weighted average assumptions [Abstract]
Expected term (in years)	5 years 9 months 18 days	5 years 8 months 12 days	5 years 8 months 19 days	6 years 4 months 24 days
Expected Volatility	54.50%	43.00%	42.90%	40.50%
Risk-free rate	0.80%	0.60%	0.50%	2.00%
Dividend rate

Equity Incentive Plan (Detail_4

Equity Incentive Plan (Details) - Schedule of stock option activity - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Schedule of stock option activity [Abstract]
Number of Shares under Option Plan, Outstanding Beginning balance	4,211,857	2,749,298
Weighted-Average Exercise Price per Option, Outstanding Beginning balance	$ 0.76	$ 0.87
Weighted- Average Remaining Contractual Life (in years), Outstanding Beginning balance	8 years 7 months 6 days	9 years
Number of Shares under Option Plan, Granted	2,378,915	2,064,603
Weighted-Average Exercise Price per Option, Granted	$ 3	$ 0.64
Weighted- Average Remaining Contractual Life (in years), Granted		9 years 3 months 18 days
Number of Shares under Option Plan, Exercised	154,902	(100,059)
Weighted-Average Exercise Price per Option , Exercised	$ 0.81	$ 0.81
Number of Shares under Option Plan, Forfeited and expired	(69,905)	(501,985)
Weighted-Average Exercise Price per Option, Forfeited and expired	$ 1.36	$ 0.83
Number of Shares under Option Plan, Outstanding Ending balance	6,365,965	4,211,857
Weighted-Average Exercise Price per Option, Outstanding Ending balance	$ 1.59	$ 0.76
Weighted- Average Remaining Contractual Life (in years), Outstanding Ending balance	8 years 4 months 24 days	8 years 7 months 6 days
Number of Shares under Option Plan, Exercisable	2,939,225	2,374,630
Weighted-Average Exercise Price per Option, Exercisable	$ 0.93	$ 0.78
Weighted- Average Remaining Contractual Life (in years), Exercisable	8 years 2 months 4 days	8 years 6 months
Number of Shares under Option Plan, Vested and expected to vest	5,955,731	4,211,857
Weighted-Average Exercise Price per Option, Vested and expected to vest	$ 1.49	$ 0.76
Weighted- Average Remaining Contractual Life (in years)	8 years 7 months 6 days	8 years 7 months 6 days

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 100,000	$ 200,000	$ 300,000	$ 300,000	$ 640,103	$ 928,110
Minimum contractual spend	$ 1,800,000		$ 1,800,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of future minimum rental payments under all non-cancelable operating leases - Non-Cancelable Operating Leases [Member]	Dec. 31, 2020USD ($)
Commitments and Contingencies (Details) - Schedule of future minimum rental payments under all non-cancelable operating leases [Line Items]
2021	$ 340,325
2022	848,602
2023	874,060
2024	900,281
2025	150,779
Thereafter
Total	$ 3,114,047

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Valuation allowance	$ 3,707,688	$ 4,691,880
Operating loss carryforwards, description			The net operating loss carryforwards generated prior to 2018 begin expiring in 2033 for federal and 2030 for state income tax purposes.
Tax credit carryforwards, description			NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions.

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets for federal income taxes - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets
Net operating loss carryforwards	$ 29,316,923	$ 25,485,398
Fixed assets	814,111	809,015
Accruals and other	247,802	568,119
Research & development credits	448,334	267,325
Share-based compensation	24,036	13,661
Valuation allowance	(30,851,206)	(27,143,518)
Net deferred tax assets

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of net operating loss carryforwards (“NOL”) for federal and state income tax - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Combined NOL Carryforwards:
Federal	$ 117,684,551	$ 103,460,873
State	$ 68,800,720	$ 54,408,623

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of net operating loss carryforwards - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Combined Credit Carryforwards:
Federal	$ 259,521	$ 147,597
State	$ 239,004	$ 151,555

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of reconciliation of income tax	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Rate reconciliation:
Federal tax benefit at statutory rate	(21.00%)	(21.00%)
State tax, net of federal benefit	(4.30%)	(5.20%)
Permanent differences	3.90%	2.40%
Research & development credits	(1.20%)	(1.10%)
Foreign rate differential	(0.60%)	(0.50%)
Other difference	(0.60%)
Change in valuation allowance	23.80%	25.40%
Tax provision

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2015
Related Party Transactions [Abstract]
Rent expens	$ 100,000	$ 100,000	$ 200,000	$ 100,000	$ 285,204	$ 287,638
Purchasing an aggregate of shares (in Shares)					6,336,666
Purchase price per share (in Dollars per share)					$ 3
Operating lease term							10 years
Owed to the related party	$ 7,000	$ 0	$ 7,000	$ 0

Employee benefit plan (Details)

Employee benefit plan (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Contributions plan amount					$ 81,673	$ 68,914
Company made contributions	$ 23,000	$ 16,000	$ 100,000	$ 46,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended			12 Months Ended
	Mar. 31, 2021	Mar. 25, 2021	Jan. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Subsequent Events (Details) [Line Items]
Debt financing total				$ 3,000,000
Purchase price				$ 3,400,000
Weighted average exercise price					$ 4.50
Stock options, grants					237,803
Equity Option [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Stock options, granted	1,843,489		540,126
Weighted average exercise price			$ 3
Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Aggregate principal amount		$ 17,000,000
Debt instrument, description		The first tranche of $15.0 million will be funded within five business days of the date of the Loan Agreement. The second tranche of $2.0 million is available, at the Company’s request, between October 30, 2021 and November 30, 2021, provided the Company achieves certain revenue and EBITDA thresholds.
Debt instrument, interest rate terms		The Company is required to pay only interest during the first eighteen months after funding of the tranche and thereafter, the Company shall repay such loan amount in thirty consecutive monthly installments of principal plus accrued interest.
Debt instrument maturity date, description		The loan facility bears an annual interest rate of the prime rate as published in the Wall Street Journal, subject to a floor 3.25%, plus 8.75%. On the final repayment date, Company is also obligated to pay a final payment fee equal to seven and one-half percent (7.5%) of the amount of the applicable advance.
Debt issuance costs		$ 200,000
Warrants purchase, description		In connection with the Loan Agreement, the Company issued the Lender warrants to purchase up to 346,500 shares (increasing to 392,700 shares upon funding of the second tranche) shares of common stock that were immediately vested with an exercise price of $3.00 per share and a term of the earlier of (i) March 24, 2031 and (ii) the third anniversary of the Company’s listing on Nasdaq.
Interest Rate Floor [Member] | Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Debt instrument, interest rate		3.25%
Prime Rate [Member] | Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Debt instrument, interest rate		8.75%

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the components of cash and restricted cash - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Schedule of reconciliation of the components of cash and restricted cash [Abstract]
Cash	$ 16,353,000	$ 20,762,084	$ 3,411,000	$ 9,603,266
Restricted cash	125,000	2,210,902	2,000,000	2,000,119
Restricted cash, non-current	207,000
Total cash and restricted cash presented in the condensed consolidated statements of cash flows	$ 16,685,000	$ 22,972,986	$ 5,411,000	$ 11,603,385

Basis of Presentation and Sum_8

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of liability deferred revenue - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Schedule of liability deferred revenue [Abstract]
Balance, beginning of period	$ 5,439,000	$ 5,510,460
Deferral of revenue	10,409,000	16,412,000
Recognition of unearned revenue	(9,963,000)	(16,483,000)
Balance, end of period	$ 5,885,000	$ 5,439,000

Basis of Presentation and Sum_9

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding	9,699,756	22,051,764	7,203,356	20,104,424
Convertible preferred stock [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding		14,812,795
Convertible preferred stock warrants [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding		2,767,836
Stock options [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding	6,365,965	4,465,548	4,211,857	2,749,298
Common stock warrants [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of diluted weighted-average shares of common stock outstanding [Line Items]
Weighted-average shares of common stock outstanding	3,333,791	5,585	2,991,499	5,585

Property and Equipment (Detai_3

Property and Equipment (Details) - Schedule of property and equipment, net - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 8,349,000	$ 8,014,216	$ 7,374,416
Less: accumulated depreciation	(7,385,000)	(7,022,000)
Property and equipment, net	964,000	992,000	1,213,026
Computer Hardware Software And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,893,000	5,557,034	5,039,545
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,184,000	2,186,239	2,072,006
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 272,000	$ 270,943	$ 262,865

Accrued expenses and other cu_4

Accrued expenses and other current liabilities (Details) - Schedule of accrued expenses and other current liabilities - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of accrued expenses and other current liabilities [Abstract]
Accrued compensation	$ 1,556,000	$ 1,711,377	$ 1,196,723
Accrued other	466,000	611,947	530,924
Accrued vendor partner liabilities	627,000	559,478	769,351
Deferred rent		20,877	210,010
Accrued professional fees	125,000	150,859	36,227
Accrued VAT and other taxes	52,000	54,755	23,013
Accrued expenses and other current liabilities	$ 2,826,000	$ 3,109,293	$ 2,766,248

Debt (Details) - Schedule of _2

Debt (Details) - Schedule of future minimum payments under the loan agreement - Loan Agreement [Member] $ in Thousands	Jun. 30, 2021USD ($)
Debt (Details) - Schedule of future minimum payments under the loan agreement [Line Items]
2021 (remaining six months)
2022	1,500
2023	6,000
2024	6,000
2025	1,500
Total	15,000
End of term charge	1,125
Subordinated note payable	16,125
Less unamortized debt discount	(1,596)
Loan Agreement borrowing net of discount	14,529
Less current portion
Loan Agreement borrowings, non-current portion	$ 14,529

Common Stock, Preferred Stock_6

Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - Schedule of warrants outstanding to acquire shares of its common stock - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Shares of common stock issuance upon exercise of warrants	3,333,791	2,991,499
June 11, 2025 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Jun. 11, 2025	Jun. 11, 2025
Shares of common stock issuance upon exercise of warrants	234	234
Exercise Price Per Warrant (in Dollars per share)	$ 96.24	$ 96.24
November 13, 2025 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Nov. 13, 2025	Nov. 13, 2025
Shares of common stock issuance upon exercise of warrants	218,078	218,078
Exercise Price Per Warrant (in Dollars per share)	$ 3	$ 3
July 28, 2027 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Jul. 28, 2027	Jul. 28, 2027
Shares of common stock issuance upon exercise of warrants	91	91
Exercise Price Per Warrant (in Dollars per share)	$ 106.17	$ 106.17
August 28, 2028 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Aug. 28, 2028	Aug. 28, 2028
Shares of common stock issuance upon exercise of warrants	1,052	1,052
Exercise Price Per Warrant (in Dollars per share)	$ 39.76	$ 39.76
September 2, 2029 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Sep. 2, 2029	Sep. 2, 2029
Shares of common stock issuance upon exercise of warrants	2,767,836	2,767,836
Exercise Price Per Warrant (in Dollars per share)	$ 2.88	$ 2.88
March 24, 2031 [Member]
Class of Warrant or Right [Line Items]
Expiration Date	Mar. 24, 2031
Shares of common stock issuance upon exercise of warrants	346,500
Exercise Price Per Warrant (in Dollars per share)	$ 3

Equity Incentive Plan (Detail_5

Equity Incentive Plan (Details) - Schedule of share-based compensation expense - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 239	$ 295	$ 623	$ 393	$ 668,072	$ 397,099
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	174	219	391	290	444,495	256,508
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	16	38	57	52	126,632	69,856
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	42	30	113	40	65,518	55,921
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 7	$ 8	$ 62	$ 11	$ 31,427	$ 14,814

Equity Incentive Plan (Detail_6

Equity Incentive Plan (Details) - Schedule of fair value of options granted was estimated	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Schedule of fair value of options granted was estimated [Abstract]
Expected term (in years)	5 years 9 months 18 days	5 years 8 months 12 days	5 years 8 months 19 days	6 years 4 months 24 days
Expected Volatility	54.50%	43.00%	42.90%	40.50%
Risk-free rate	0.80%	0.60%	0.50%	2.00%
Dividend rate

Equity Incentive Plan (Detail_7

Equity Incentive Plan (Details) - Schedule of stock option activity - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Schedule of stock option activity [Abstract]
Number of Shares under Option Plan, Outstanding Beginning balance	4,211,857	2,749,298
Weighted-Average Exercise Price per Option, Outstanding Beginning balance	$ 0.76	$ 0.87
Weighted- Average Remaining Contractual Life (in years), Outstanding Beginning balance	8 years 7 months 6 days	9 years
Number of Shares under Option Plan, Granted	2,378,915	2,064,603
Weighted-Average Exercise Price per Option, Granted	$ 3	$ 0.64
Number of Shares under Option Plan, Exercised	(154,902)	100,059
Weighted-Average Exercise Price per Option , Exercised	$ 0.81	$ 0.81
Number of Shares under Option Plan, Forfeited and expired	(69,905)	(501,985)
Weighted-Average Exercise Price per Option, Forfeited and expired	$ 1.36	$ 0.83
Number of Shares under Option Plan, Outstanding Ending balance	6,365,965	4,211,857
Weighted-Average Exercise Price per Option, Outstanding Ending balance	$ 1.59	$ 0.76
Weighted- Average Remaining Contractual Life (in years), Outstanding Ending balance	8 years 4 months 24 days	8 years 7 months 6 days
Number of Shares under Option Plan, Exercisable	2,939,225	2,374,630
Weighted-Average Exercise Price per Option, Exercisable	$ 0.93	$ 0.78
Weighted- Average Remaining Contractual Life (in years), Exercisable	8 years 2 months 4 days	8 years 6 months
Number of Shares under Option Plan, Vested and expected to vest	5,955,731	4,211,857
Weighted-Average Exercise Price per Option, Vested and expected to vest	$ 1.49	$ 0.76
Weighted- Average Remaining Contractual Life (in years)	8 years 7 months 6 days	8 years 7 months 6 days

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of future minimum rental payments under all non-cancelable operating leases $ in Thousands	Jun. 30, 2021USD ($)
Schedule of future minimum rental payments under all non-cancelable operating leases [Abstract]
2021 (remaining six months)	$ 276
2022	849
2023	874
2024	900
2025	151
Total	$ 3,050